<SEC-DOCUMENT>0001104659-22-108980.txt : 20221017
<SEC-HEADER>0001104659-22-108980.hdr.sgml : 20221017
<ACCEPTANCE-DATETIME>20221017060041
ACCESSION NUMBER:		0001104659-22-108980
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20221014
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221017
DATE AS OF CHANGE:		20221017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		221312470

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2227932d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:vrna="http://veronapharma.com/20221014">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_vrna_veronapharma.com_20221014 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20221014_20221014 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001657312 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityCentralIndexKey">0001657312</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-14to2022-10-14" id="xdx2ixbrl0012" name="dei:EntityIncorporationStateCountryCode">X0</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-14to2022-10-14" id="xdx2ixbrl0018" name="dei:EntityAddressCountry">GB</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="vrna-20221014.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-10-14to2022-10-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-14</xbrli:startDate>
        <xbrli:endDate>2022-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20221014__20221014_zMEzEQm5oFg2"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20221014__20221014_zkc2OUzl9zEj"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 14, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityRegistrantName_c20221014__20221014_zYjV78whqZt8"><b><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityRegistrantName">Verona
Pharma plc</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_dxL_c20221014__20221014_zR3ENIfzbCOd" title="::XDX::X0" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl0012">United
    Kingdom</span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_900_edei--EntityFileNumber_c20221014__20221014_zBhcV1XDoEfg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityFileNumber">001-38067</ix:nonNumeric></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20221014__20221014_zY6Vf0NF9Z71" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityTaxIdentificationNumber">98-1489389</ix:nonNumeric></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 34%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State
                                            or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="vertical-align: bottom; width: 1%; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS
                                            Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--EntityAddressAddressLine1_c20221014__20221014_zBSYtul9hdU1"><b><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityAddressAddressLine1">3
More London Riverside</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityAddressCityOrTown_c20221014__20221014_zumcvqj38Xv7"><b><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityAddressCityOrTown">London</ix:nonNumeric>
</b></span><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20221014__20221014_zjZEWyzpb9B3"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:EntityAddressPostalZipCode">SE1 2RE</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCountry_dxL_c20221014__20221014_zxJ24DNMmhF7" title="::XDX::GB"><span style="-sec-ix-hidden: xdx2ixbrl0018">United Kingdom</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip
Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>+<span id="xdx_905_edei--CountryRegion_c20221014__20221014_zI2ZkoX8AI2h"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:CountryRegion">44</ix:nonNumeric>
</span></b><b><span id="xdx_906_edei--CityAreaCode_c20221014__20221014_ztQYm1Ihdni9"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:CityAreaCode">203</ix:nonNumeric></span></b><b> <span id="xdx_90F_edei--LocalPhoneNumber_c20221014__20221014_zRdBTohyp207"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:LocalPhoneNumber">283
4200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span id="xdx_90A_edei--WrittenCommunications_c20221014__20221014_zVuDOmDoKVZh" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span id="xdx_903_edei--SolicitingMaterial_c20221014__20221014_zn2kWgPtAFW9" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange
    Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span id="xdx_908_edei--PreCommencementTenderOffer_c20221014__20221014_zRqycPaSdvld" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
    the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20221014__20221014_zXiGVdqThLp9" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
    the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b)&#160;of
the Act:&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Title
    of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Name
    of each exchange on which <br />
    registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_901_edei--Security12bTitle_c20221014__20221014_zGb8x2KqzXdk" style="font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:Security12bTitle">Ordinary
    shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_908_edei--TradingSymbol_c20221014__20221014_za93bsPlsLvf" style="font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" name="dei:TradingSymbol">VRNA</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_905_edei--SecurityExchangeName_c20221014__20221014_zRBTMMYqgpql" style="font-size: 10pt"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric> </span><span style="font-size: 10pt"><br />
    (Nasdaq Global Market)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>* The ordinary shares are represented by American
Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section&#160;12(a)&#160;of the Securities
Exchange Act of 1934, as amended, pursuant to Rule&#160;12a-8 thereunder.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20221014__20221014_zo5PxRRFsKAd" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span id="xdx_901_edei--EntityExTransitionPeriod_c20221014__20221014_zrvK1lJ9VzL9" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-10-14to2022-10-14" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item 1.01.
</b></span><b>Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On October
14</span>, 2022 (the &#8220;Effective Date&#8221;), Verona Pharma plc (the &#8220;Company&#8221;) and Verona Pharma, Inc. (&#34;Verona
U.S.&#34; and together with the Company, the &#8220;Borrowers&#8221;) entered into a term loan facility of up to $150.0 million (the
&#8220;Term Loan&#8221;), consisting of term loan advances in an aggregate amount of $10.0 million funded on the Effective Date (the
&#8220;Term A Loan&#8221;), a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0 million
(the &#8220;Term B Loan&#8221;), a term loan advance available subject to certain terms and conditions in an aggregate amount of $20.0
million (the &#8220;Term C Loan&#8221;), a term loan advance available subject to certain terms and conditions in an aggregate amount
of $60.0 million (the &#8220;Term D Loan&#8221;) and a term loan advance available in the sole discretion of the lenders and subject
to certain terms and conditions in an aggregate amount of $50.0 million (the &#8220;Term E Loan&#8221;), with Oxford Finance Luxembourg
S.&#192; R.L., a Luxembourg private limited liability company (soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e), as collateral
agent and as a lender (&#8220;Oxford&#8221;), and the lenders party thereto (the &#8220;Lenders&#8221;). The proceeds of the Term Loan
will be used for general corporate and working capital purposes, and a portion of the proceeds of the Term A Loan was used by the Borrowers
on the Effective Date to repay in full the existing outstanding indebtedness owed by the Borrowers to Silicon Valley Bank, a California
corporation (&#8220;SVB&#8221;), under that certain Loan and Security Agreement, dated as of November 19, 2020, by and among SVB and
the Borrowers (the &#8220;Prior Loan Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Term
Loan is governed by a loan and security agreement, dated as of October 14</span>, 2022, by and among the Borrowers, Oxford and the Lenders
(the &#8220;Loan Agreement&#8221;). The Term B Loan is available as of the Effective Date through and including March 31, 2023, subject
to customary terms and conditions. The Term C Loan will be available, subject to customary terms and conditions, during the period commencing
on the later of January 1, 2024 and the date on which the Borrowers receive positive ENHANCE-1 data in the Phase 3 clinical trial for
ensifentrine sufficient to support the submission of a New Drug Application (&#8220;NDA&#8221;) with the United States Food and Drug
Administration (the &#8220;FDA&#8221;) for ensifentrine through and including March 29, 2024. The Term D Loan will be available, subject
to customary terms and conditions, during the period commencing on the later of October 1, 2024 and the date on which the Borrowers receive
final approval from the FDA for the Borrowers' NDA for ensifentrine through and including December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Term
Loan will mature on October 1, 2027. Each advance under the Loan Agreement accrues interest at a floating per annum rate (the
&#8220;Basic Rate&#8221;) equal to (a) the greater of (i) the 1-Month CME Term SOFR (as defined in the Loan Agreement) reference
rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) two and
thirty-eight hundredths percent (2.38%), plus (b) five and fifty hundredths percent (5.50%). Notwithstanding the foregoing, (i) in
no event shall the Basic Rate (x) for the Term A Loan be less than seven and eighty-eight hundredths percent (7.88%) and (y) for
each other Term Loan be less than the Basic Rate on the business day immediately prior to the funding date of such Term Loan, (ii)
the Basic Rate for the Term A Loan for the period from the Effective Date through and including October 31, 2022 shall be 8.54205%
and (iii) the Basic Rate for each Term Loan shall not increase by more than two hundred basis points (2.00%) above the applicable
Basic Rate as of the funding date of each such Term Loan. The Term Loan provides for interest-only payments on a monthly basis until
the payment date immediately preceding December 1, 2025, if the Term D Loan is not made, and December 1, 2026, if the Term D Loan is
made. Thereafter, amortization payments will be payable monthly in equal installments of principal plus monthly payments of accrued
interest. Upon repayment (whether at maturity, upon acceleration or by prepayment or otherwise), the Borrowers shall make a final
payment to the Lenders in the amount of 1.30% to 3.00% of the aggregate Term Loans advanced, depending on the tranche of Term Loan
(the &#8220;Final Payment&#8221;). The Borrowers may prepay the Term Loan in full or in part provided that the Borrowers (i) provide
ten (10) days&#8217; prior written notice to Oxford, (ii) pays on the date of such prepayment (A) all outstanding principal plus
accrued and unpaid interest, (B) a prepayment fee of 2.00% of the Term Loans advanced if paid on or before the first anniversary of
the funding date of such Term Loans; 1.50% of the Term Loans advanced if paid after the first anniversary of the funding date of
such Term Loans and on or before the second anniversary of such funding date; 1.00% of the Term Loans advanced if paid after the
second anniversary of the funding date of such Term Loans and on or before the third anniversary of such funding date; and no
prepayment fee if paid thereafter and prior to maturity, (C) the Final Payment and (D) all other sums, if any, that shall become due
and payable under the Loan Agreement, including interest at the default rate with respect to any past due amounts. Amounts
outstanding during an event of default are payable upon the Required Lenders&#8217; (as defined in the Loan Agreement) demand and
shall accrue interest at an additional rate of 5.00% per annum and (iii) any partial prepayment of the Term Loans shall be in a
denomination that is a whole number multiple of Five Million Dollars ($5,000,000.00).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Term Loan is secured by a lien on substantially all of the assets
of the Borrowers, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments
and proceeds from the sale, licensing or disposition of intellectual property. The Borrowers have also granted Oxford and the Lenders
a negative pledge with respect to their intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Loan Agreement contains customary covenants and representations,
including but not limited to financial reporting obligations and limitations on dividends, dispositions, indebtedness, collateral, investments,
distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, transactions with affiliates and subsidiaries.
The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification
rights for the benefit of Oxford and the Lenders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The events of default under the Loan Agreement include, but are not
limited to, the Borrowers&#8217; failure to make any payments of principal or interest under the Loan Agreement or other transaction documents,
the Borrowers&#8217; breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the
occurrence of a material adverse change, any Borrower making a false or misleading representation or warranty in any material respect
under the Loan Agreement, any Borrower&#8217;s insolvency or bankruptcy, any attachment or judgment on any Borrower&#8217;s assets of
at least $500,000, the occurrence of any default under any agreement or obligation of any Borrower involving indebtedness in excess of
$500,000, or delisting of the Company&#8217;s American Depositary Shares from the Nasdaq Capital Market. If an event of default occurs,
Oxford is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Loan Agreement is a summary, and is
qualified in its entirety by reference to such document, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K, and
is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the entry into the Loan Agreement, on the Effective
Date, the Borrowers repaid in full all outstanding indebtedness and terminated all commitments under the Prior Loan Agreement, the material
terms of which have been disclosed previously. The aggregate principal amount of the loan outstanding under the Prior Loan Agreement was
$5.0 million at the time of repayment. SVB&#8217;s security interest in the Borrowers&#8217; assets under the Prior Loan Agreement were
terminated in connection with the Borrowers&#8217; discharge of their indebtedness thereunder. The Borrowers did not incur any penalties,
but did incur a prepayment fee and a termination fee, as a result of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item 1.02.
</b></span><b>Termination of a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth above in Item 1.01 of this Current Report
on Form 8-K regarding the repayment and termination of the Prior Loan Agreement is incorporated into this Item 1.02 by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item </b></span><b>2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth above in Item 1.01 of this Current Report
on Form 8-K regarding the Borrowers&#8217; direct financial obligation under the Loan Agreement is incorporated into this Item 2.03 by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item </b></span><b>9.01.
Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br />
    Number</b></span></td>
    <td style="padding: 0.25pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 88%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2227932d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="padding: 0.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><a href="tm2227932d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
and Security Agreement, dated as of October 14</span><span style="font-size: 10pt">, 2022, by and among Verona Pharma plc, Verona Pharma,
Inc., Oxford Finance Luxembourg S.&#192; R.L., as collateral agent and as a lender, and the other lenders party thereto</span></a></td></tr>
  <tr>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File &#8211; the cover page XBRL tags are embedded within the Inline Instance XBRL document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VERONA PHARMA PLC</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </span><span style="font-size: 10pt">October 17, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;/s/ David Zaccardelli, Pharm.D.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;David Zaccardelli, Pharm.D.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PXQdirJLhw5xyhgi3haXSXFrRlp/9ki+pXVDDIGQnPPlCBGKjDa6QYbzqszhiG3XKIdQYo2M5oLekW53CfhZ4lVbx8q4Yf2BKXkGPTOfLJS/D86HtlglEM2m8XIaS4hkIudQ7EXw1VMyta7QOK0aUKaCgqljjU5xP344qhcZavsh6YRsNZkE5CQa5TfEkYzhQA/1JL5ZyPNUBOFQgciY7t035m4dtbBusPVZdkT/HXwA3xxJGw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2227932d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOAN AND SECURITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
LOAN AND SECURITY AGREEMENT</B></FONT> (as the same may from time to time be amended, restated, amended and restated, supplemented or
otherwise modified, this &ldquo;<B>Agreement</B>&rdquo;) dated as of October&nbsp;14, 2022 (the &ldquo;<B>Effective Date</B>&rdquo;)
among OXFORD FINANCE LUXEMBOURG S.&Agrave; R.L., a Luxembourg private limited liability company (soci&eacute;t&eacute; &agrave; responsabilit&eacute;
limit&eacute;e) with registered office at 2 route d&rsquo;Arlon, 8008 Strassen, Grand Duchy of Luxembourg and registered with the Luxembourg
commercial register under number B243395, acting in respect of its Compartment 7 (&ldquo;<B>Oxford</B>&rdquo;), as collateral agent (in
such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders listed on <U>Schedule&nbsp;1.1</U> hereof or otherwise a party hereto
from time to time including Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;),
VERONA PHARMA PLC, a public limited company incorporated and existing under the laws of England with company registration number 05375156
with offices located at 3 More London Riverside, London SE1 2RE, United Kingdom (&ldquo;<B>Parent</B>&rdquo;) and VERONA PHARMA,&nbsp;INC.,
a Delaware corporation with offices located at 8045 Arco Corporate Drive, Suite&nbsp;130, Raleigh, NC 27617, USA (&ldquo;<B>US Sub</B>&rdquo;)
(Parent and US Sub, individually and collectively, jointly and severally, &ldquo;<B>Borrower</B>&rdquo;), provides the terms on which
the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>ACCOUNTING
AND OTHER TERMS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>Accounting
terms not defined in this Agreement shall be construed in accordance with GAAP. Calculations and determinations must be made in accordance
with GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section&nbsp;13. All other
terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are
defined therein. All references to &ldquo;<B>Dollars</B>&rdquo; or &ldquo;<B>$</B>&rdquo; are United States Dollars, unless otherwise
noted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>LOANS
AND TERMS OF PAYMENT</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Promise
to Pay.</B> Borrower hereby unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans advanced
to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance
with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Term
Loans</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Availability</U>.
(i)&nbsp;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower
on the Effective Date in an aggregate amount of Ten Million Dollars ($10,000,000.00) according to each Lender&rsquo;s Term&nbsp;A Loan
Commitment as set forth on <U>Schedule&nbsp;1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term&nbsp;A
Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term&nbsp;A Loans</B>&rdquo;). After repayment, no Term&nbsp;A Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term
loans to Borrower in an aggregate amount of Ten Million Dollars ($10,000,000.00) according to each Lender&rsquo;s Term&nbsp;B Loan Commitment
as set forth on <U>Schedule&nbsp;1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term&nbsp;B Loan</B>&rdquo;,
and collectively as the &ldquo;<B>Term&nbsp;B Loans</B>&rdquo;). After repayment, no Term&nbsp;B Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to make term
loans to Borrower in an aggregate amount of Twenty Million Dollars ($20,000,000.00) according to each Lender&rsquo;s Term&nbsp;C Loan
Commitment as set forth on <U>Schedule&nbsp;1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term&nbsp;C
Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term&nbsp;C Loans</B>&rdquo;). After repayment, no Term&nbsp;C Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Fourth Draw Period, to make term
loans to Borrower in an aggregate amount of Sixty Million Dollars ($60,000,000.00) according to each Lender&rsquo;s Term&nbsp;D Loan
Commitment as set forth on <U>Schedule&nbsp;1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term&nbsp;D
Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term&nbsp;D Loans</B>&rdquo;). After repayment, no Term&nbsp;D Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions of this Agreement, the Lenders may, in their sole discretion and upon Borrower&rsquo;s request, agree to
make term loans to Borrower in an aggregate amount equal to Fifty Million Dollars ($50,000,000.00) in a single advance and, if made,
according to a commitment schedule to be provided by the Lenders prior to the Funding Date of such term loans (such term loans are hereinafter
referred to singly as a &ldquo;<B>Term E Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term E Loans</B>&rdquo;; each Term A Loan,
Term B Loan, Term C Loan, Term D Loan and Term E Loan is hereinafter referred to singly as a &ldquo;<B>Term Loan</B>&rdquo;, and the
Term A Loans, the Term B Loans, the Term C Loans, the Term D Loans and the Term E Loans are hereinafter referred to collectively as the
 &ldquo;<B>Term Loans</B>&rdquo;). After repayment, no Term E Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1<SUP>st</SUP>) Payment Date following the first full
calendar month to occur after the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter
through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each
Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the
last calendar day of the month in which such Term Loan funds. Commencing on the Amortization Date, and continuing on the Payment Date
of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in
arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon:
(1)&nbsp;the amount of such Lender&rsquo;s Term&nbsp;Loan, (2)&nbsp;the effective rate of interest, as determined in Section&nbsp;2.3(a),
and (3)&nbsp;a repayment schedule equal to (i)&nbsp;twenty-three (23) months, if the Term D Loans are not made and (ii)&nbsp;eleven (11)
months, if the Term D Loans are made. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and
payable in full on the Maturity Date. Each Term&nbsp;Loan may only be prepaid in accordance with Sections 2.2(c)&nbsp;and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mandatory
Prepayments</U>. If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to
Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i)&nbsp;all outstanding
principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii)&nbsp;the Final Payment, (iii)&nbsp;the
Prepayment Fee, plus (iv)&nbsp;all other Obligations that are due and payable, including Lenders&rsquo; Expenses and interest at the
Default Rate (if the Required Lenders so elect) with respect to any past due amounts. Notwithstanding (but without duplication with)
the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the
Term Loans in full, Borrower shall pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share,
any remaining portion of the Final Payment in respect of the Term Loan(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Permitted
Prepayment of Term Loans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided
Borrower (i)&nbsp;provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10)&nbsp;days prior
to such prepayment, and (ii)&nbsp;pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective
Pro Rata Share, an amount equal to the sum of (A)&nbsp;all outstanding principal of the Term Loans plus accrued and unpaid interest thereon
through the prepayment date, (B)&nbsp;the Final Payment, (C)&nbsp;the Prepayment Fee, plus (D)&nbsp;all other Obligations that are due
and payable, including Lenders&rsquo; Expenses and interest at the Default Rate (if the Required Lenders so elect) with respect to any
past due amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything herein to the contrary, Borrower shall also have the option to prepay part of Term Loans advanced by the Lenders under this
Agreement, provided Borrower (i)&nbsp;provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten
(10)&nbsp;days prior to such prepayment, (ii)&nbsp;prepays such part of the Term Loans in a denomination that is a whole number multiple
of Five Million Dollars ($5,000,000.00), and (iii)&nbsp;pays to the Lenders on the date of such prepayment, payable to each Lender in
accordance with its respective Pro Rata Share, an amount equal to the sum of (A)&nbsp;the portion of outstanding principal of such Term
Loans plus all accrued and unpaid interest thereon through the prepayment date, (B)&nbsp;the applicable Final Payment, and (C)&nbsp;all
other Obligations that are then due and payable, including Lenders&rsquo; Expenses and interest at the Default Rate (if the Required
Lenders so elect) with respect to any past due amounts, and (D)&nbsp;the applicable pro-rated Prepayment Fee with respect to the portion
of such Term Loans being prepaid. For the purposes of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts
under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section&nbsp;2.2(b)&nbsp;on
a pro-rata basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Interest on the Credit Extensions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Interest
Rate.</U> Subject to Section&nbsp;2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per
annum rate equal to the Basic Rate, determined by Collateral Agent (x)&nbsp;on the Funding Date of the applicable Term Loan and (y)&nbsp;monthly
thereafter, which interest shall be payable monthly in arrears in accordance with Sections 2.2(b)&nbsp;and 2.3(e). Interest shall accrue
on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding
under such Term Loan through and including the day on which such Term Loan is paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Default
Rate</U>. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a floating
per annum rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the &ldquo;<B>Default Rate</B>&rdquo;).
Payment or acceptance of the increased interest rate provided in this Section&nbsp;2.3(b)&nbsp;is not a permitted alternative to timely
payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>360-Day
Year</U>. Interest shall be computed on the basis of a three hundred sixty (360) day year, and the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Debit
of Accounts</U>. Collateral Agent and each Lender may debit (or ACH) any deposit accounts, maintained by Borrower or any of its Subsidiaries,
starting with the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes the Lenders under
the Loan Documents when due. Any such debits (or ACH activity) shall not constitute a set-off. Without limiting the foregoing, Collateral
Agent and each Lender shall use commercially reasonable efforts to notify Borrower for the reasons of debiting of any amounts (other
than principal and interest payments) debited from Borrower&rsquo;s deposit accounts in respect of this Agreement after such debit has
been made; provided, however, failure to provide such notice shall not be considered a breach of any provision hereof by Collateral Agent
or any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payments</U>.
Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective Lender
to which such payments are owed, at such Lender&rsquo;s office in immediately available funds on the date specified herein. Unless otherwise
provided, interest is payable monthly on the Payment Date of each month. Payments of principal and/or interest received after 2:00 p.m.&nbsp;Eastern
time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business
Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All
payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees,
expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States
and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Secured
Promissory Notes.</B> The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form attached as <U>Exhibit&nbsp;D
</U>hereto (each a &ldquo;<B>Secured Promissory Note</B>&rdquo;), and shall be repayable as set forth in this Agreement. Borrower irrevocably
authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment
of principal on such Lender&rsquo;s Secured Promissory Note, an appropriate notation on such Lender&rsquo;s Secured Promissory Note Record
reflecting the making of such Term Loan or (as the case may be) the receipt of such payment. The outstanding amount of each Term Loan
set forth on such Lender&rsquo;s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and
unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender&rsquo;s Secured Promissory
Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document
to make payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a
Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note<B>, </B>Borrower shall issue, in lieu thereof,
a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Fees.
</B>Borrower shall pay to Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Good
Faith Deposit</U>. An amount of One Hundred Thousand Dollars ($100,000.00) has been received by Collateral Agent as a good faith deposit
from Borrower on or about September&nbsp;9, 2022, which amount shall be applied towards the Lenders&rsquo; Expenses due hereunder that
have been incurred through the Effective Date. For the purposes of clarity, Borrower shall be responsible for the entire amount of the
Lenders&rsquo; Expenses payable under Section&nbsp;2.5(d);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Final
Payment</U>. The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Prepayment
Fee</U>. The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lenders&rsquo;
Expenses</U>. All Lenders&rsquo; Expenses (including reasonable and documented attorneys&rsquo; fees and expenses for documentation and
negotiation of this Agreement) incurred through and after the Effective Date, when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Withholding.
</B></FONT>Provided the Borrower has timely received from each Lender a Tax Certificate (as defined below), payments received by the
Lenders (or the Collateral Agent, if applicable) from Borrower hereunder will be made free and clear of and without deduction for any
and all present or future U.S. federal income Taxes. If at any time any Governmental Authority, applicable law, regulation or international
agreement requires Borrower to make any such withholding or deduction from any such payment or other sum payable hereunder to the Lenders,
Borrower shall be permitted to make such withholding or deduction and hereby covenants and agrees that the amount due from Borrower with
respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of
such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding
or deduction been required and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority. Borrower
will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such withholding
payment; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment
is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower.
The agreements and obligations of Borrower contained in this Section&nbsp;2.6 shall survive the termination of this Agreement. On or
prior to the date of this Agreement, each Lender shall deliver, and upon a Lender Transfer, the applicable successor or assign shall
deliver, to Borrower a complete and properly executed IRS Form&nbsp;W-9 or an appropriate IRS Form&nbsp;W-8, as applicable, certifying
that such Lender is exempt from U.S. federal withholding tax (including backup withholding) or any similar or successor certificate designated
by the IRS (a &ldquo;<B>Tax Certificate</B>&rdquo;). Notwithstanding anything to the contrary in this Section&nbsp;2.6, from and after
the failure of any Lender to so deliver such a Tax Certificate, the amount due from Borrower with respect to such payment or other sum
payable hereunder shall not be required to be increased to the extent necessary to ensure that, after the making of such required withholding
or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding or deduction been required
and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority, until such time as the Tax Certificate
has been delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>CONDITIONS
OF LOANS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Conditions
Precedent to Initial Credit Extension.</B> Each Lender&rsquo;s obligation to make a Term&nbsp;A Loan is subject to the condition precedent
that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent
and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary
or appropriate, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;original
Loan Documents, each duly executed by Borrower and each Subsidiary, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;duly
executed original Control Agreements with respect to any Collateral Accounts maintained by Borrower or any of its Subsidiaries to the
extent required under Section&nbsp;6.6;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;duly
executed original Secured Promissory Notes in favor of each Lender according to its Term&nbsp;A Loan Commitment Percentage;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
certificate(s)&nbsp;for the Shares, together with Assignment(s)&nbsp;Separate from Certificate, duly executed in blank;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Operating Documents and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent
agency) of Borrower&rsquo;s and such Subsidiaries&rsquo; jurisdiction of organization or formation and each jurisdiction in which Borrower
and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date<B>;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
completed Perfection Certificate for Borrower and each of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Annual Projections, for the current calendar year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;duly
executed original Corporate Certificate for Borrower and each Subsidiary that is a party to the Loan Documents, in a form acceptable
to Collateral Agent and the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;certified
copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as Collateral
Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such
financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated
or released;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
landlord&rsquo;s consent executed in favor of Collateral Agent in respect of US Sub&rsquo;s headquarters locations, and each other of
Borrower&rsquo;s and each Subsidiaries&rsquo; leased locations in the United States where Borrower or any Subsidiary maintains Collateral
having a book value in excess of Five Hundred Thousand Dollars ($500,000.00);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
bailee waiver executed in favor of Collateral Agent in respect of each third party bailee where Borrower or any Subsidiary maintains
Collateral having a book value in excess of Five Hundred Thousand Dollars ($500,000.00);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
duly executed United States legal opinion of counsel to Borrower dated as of the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
duly executed English legal opinion of counsel to Lenders dated as of the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;duly
executed English Security Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;evidence
satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section&nbsp;6.5 hereof are in full force and
effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral
Agent, for the ratable benefit of the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
payoff letter from Silicon Valley Bank in respect of the Existing Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;evidence
that (i)&nbsp;the Liens securing the Existing Indebtedness will be terminated and (ii)&nbsp;the documents and/or filings evidencing the
perfection of such Liens, including without limitation any financing statements and/or control agreements, have or will, concurrently
with the initial Credit Extension, be terminated; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;payment
of the fees and Lenders&rsquo; Expenses then due as specified in Section&nbsp;2.5 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Conditions
Precedent to all Credit Extensions.</B> The obligation of each Lender to make each Credit Extension, including the initial Credit Extension,
is subject to the following conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;receipt
by Collateral Agent of an executed Disbursement Letter in the form of <U>Exhibit&nbsp;B</U> attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
representations and warranties in Section&nbsp;5 hereof shall be true, accurate and complete in all material respects on the date of
the Disbursement Letter and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not
be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided,
further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all
material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension.
Each Credit Extension is Borrower&rsquo;s representation and warranty on that date that the representations and warranties in Section&nbsp;5
hereof are true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable
to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further
that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material
respects as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
such Lender&rsquo;s sole but reasonable discretion, there has not been a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes, in number, form and content reasonably
acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension
made by such Lender after the Effective Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;payment
of the fees and Lenders&rsquo; Expenses then due as specified in Section&nbsp;2.5 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Covenant
to Deliver.</B> Borrower agrees to deliver to Collateral Agent, to the extent applicable, and the Lenders each item required to be delivered
to Collateral Agent or any Lender under this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that
a Credit Extension made prior to the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by Collateral
Agent or any Lender of Borrower&rsquo;s obligation to deliver such item, and any such Credit Extension in the absence of a required item
shall be made in each Lender&rsquo;s reasonable discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Procedures
for Borrowing.</B></FONT> Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth
in this Agreement, to obtain a Term Loan (other than for the Term Loan funded on the Effective Date), Borrower shall notify the Lenders
(which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 2:00 p.m.&nbsp;Eastern time ten (10)&nbsp;Business
Days prior to the date the Term Loan is to be made. Together with any such electronic, facsimile or telephonic notification, Borrower
shall deliver to the Lenders by electronic mail or facsimile a completed Disbursement Letter executed by a Responsible Officer or his
or her designee. The Lenders may rely on any telephone notice given by a person whom a Lender reasonably believes is a Responsible Officer
or designee. On the Funding Date, each Lender shall credit and/or transfer (as applicable) to the Designated Deposit Account, an amount
equal to its Term Loan Commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>CREATION
OF SECURITY INTEREST</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Grant
of Security Interest.</B> Borrower hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and
performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit
of the Lenders, the Collateral (but for the purposes of this Section&nbsp;4.1, excluding all of the English Collateral), wherever located,
whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Borrower represents, warrants, and covenants
that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the
Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to have priority to Collateral Agent&rsquo;s
Lien. If Borrower shall acquire a commercial tort claim (as defined in the Code) greater than Two Hundred Fifty Thousand Dollars ($250,000.00),
in the aggregate, Borrower shall promptly notify Collateral Agent in a writing signed by Borrower, as the case may be, of the general
details thereof (and further details as may be required by Collateral Agent) and grant to Collateral Agent, for the ratable benefit of
the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such
writing to be in form and substance reasonably satisfactory to Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Agreement is terminated,
Collateral Agent&rsquo;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are
repaid in full in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time
as the Lenders&rsquo; obligation to make Credit Extensions has terminated, Collateral Agent shall, at the sole cost and expense of Borrower,
release its Liens in the Collateral and all rights therein shall revert to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Authorization
to File Financing Statements.</B> Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required
to perfect Collateral Agent&rsquo;s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions
to perfect or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Pledge
of Collateral.</B></FONT> Borrower hereby pledges, assigns and grants to Collateral Agent, for the ratable benefit of the Lenders, a
security interest in all the Shares (but for the purposes of this Section&nbsp;4.3, excluding all Shares that are part of the English
Collateral), together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights
to subscribe for securities declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as
security for the performance of the Obligations. On the Effective Date, or, to the extent not certificated as of the Effective Date,
within twenty (20) Business Days of the certification of any Shares, the certificate or certificates for the Shares will be delivered
to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by Borrower. To the extent a pledge of the Shares
to the Collateral Agent is required by the terms and conditions governing such Shares to be reflected on the books of the applicable
issuer, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge
of such Shares. Upon the occurrence and during the continuance of an Event of Default hereunder, Collateral Agent may effect the transfer
of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and cause new
(as applicable) certificates representing such securities to be issued in the name of Collateral Agent or its transferee. Borrower will
execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request to perfect
or continue the perfection of Collateral Agent&rsquo;s security interest in the Shares. Unless an Event of Default shall have occurred
and be continuing, Borrower shall be entitled to (i)&nbsp;exercise any voting rights with respect to the Shares and to give consents,
waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action
taken which would be inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of
such terms and (ii)&nbsp;to receive and retain any and all dividends, interest and other distributions paid in respect of the Shares
to the extent that the payment thereof is not otherwise inconsistent with the terms of this Agreement. All such rights to vote and give
consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default. After all Events of Default
have been waived in writing by Collateral Agent and the Lenders, Borrower shall regain the exclusive right to exercise the voting and/or
consensual rights and powers that Borrower would otherwise be entitled to exercise and the right to receive and retain any dividends
and interest payments from and after the effective date of such waiver that Borrower would otherwise be entitled to receive and retain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>REPRESENTATIONS
AND WARRANTIES</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower represents and warrants
to Collateral Agent and the Lenders as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Due
Organization, Authorization: Power and Authority.</B> Borrower and each of its Subsidiaries is duly existing and in good standing as
a Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and
licensed to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property
requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change. In
connection with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate
signed by an officer of Borrower or such Subsidiary (each a &ldquo;<B>Perfection Certificate</B>&rdquo; and collectively, the &ldquo;<B>Perfection
Certificates</B>&rdquo;). Borrower represents and warrants that (a)&nbsp;Borrower and each of its Subsidiaries&rsquo; exact legal name
is that which is indicated on its respective Perfection Certificate and on the signature page&nbsp;of each Loan Document to which it
is a party; (b)&nbsp;Borrower and each of its Subsidiaries is an organization of the type and is organized in the jurisdiction set forth
on its respective Perfection Certificate; (c)&nbsp;each Perfection Certificate accurately sets forth each of Borrower&rsquo;s and its
Subsidiaries&rsquo; organizational identification number or accurately states that Borrower or such Subsidiary has none; (d)&nbsp;each
Perfection Certificate accurately sets forth Borrower&rsquo;s and each of its Subsidiaries&rsquo; place of business, or, if more than
one, its chief executive office as well as Borrower&rsquo;s and each of its Subsidiaries&rsquo; mailing address (if different than its
chief executive office); (e)&nbsp;Borrower and each of its Subsidiaries (and each of its respective predecessors) have not, in the past
five (5)&nbsp;years, changed its jurisdiction of organization, organizational structure or type, or any organizational number assigned
by its jurisdiction; and (f)&nbsp;all other information set forth on the Perfection Certificates pertaining to Borrower and each of its
Subsidiaries, is accurate and complete in all material respects (it being understood and agreed that Borrower and each of its Subsidiaries
may from time to time update certain information in the Perfection Certificates (including the information set forth in clause (d)&nbsp;above)
after the Effective Date to the extent permitted by one or more specific provisions in this Agreement); such updated Perfection Certificates
subject to the review and approval of Collateral Agent unless such facts, events or circumstances being updated first arose or occurred
after the Effective Date and do not constitute a breach, default, or Event of Default under this Agreement or any other Loan Document.
If Borrower or any of its Subsidiaries is not now a Registered Organization but later becomes one, Borrower shall notify Collateral Agent
of such occurrence and provide Collateral Agent with such Person&rsquo;s organizational identification number within five (5)&nbsp;Business
Days of receiving such organizational identification number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is a party have been duly
authorized, and do not (i)&nbsp;conflict with any of Borrower&rsquo;s or such Subsidiaries&rsquo; Operating Documents, </FONT>(ii)&nbsp;contravene,
conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii)&nbsp;contravene, conflict
or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower
or such Subsidiary, or any of their property or assets may be bound or affected, (iv)&nbsp;require any action by, filing, registration,
or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already
been obtained and are in full force and effect or are being obtained pursuant to Section&nbsp;6.1(b)), or (v)&nbsp;constitute an event
of default under any material agreement by which Borrower or any of such Subsidiaries, or their respective properties, is bound. Neither
Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is
bound in which such default could reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Collateral.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
and each of its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it
purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and neither Borrower nor
any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the
Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent
in connection herewith or otherwise informed the Collateral Agent in writing with respect of which Borrower or such Subsidiary has given
Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected security interest therein, pursuant
to the terms of Section&nbsp;6.6(b). The Accounts are bona fide, existing obligations of the Account Debtors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
the Effective Date, and except as disclosed on the Perfection Certificate or as permitted under this Agreement, (i)&nbsp;the Collateral
is not in the possession of any third party bailee (such as a warehouse), and (ii)&nbsp; no such third party bailee possesses components
of the Collateral in excess of Five Hundred Thousand Dollars ($500,000.00). None of the components of the Collateral shall be maintained
at locations other than as disclosed in the Perfection Certificates on the Effective Date or as permitted pursuant to Section&nbsp;6.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Inventory held and released for commercial sale by or for the benefit of Borrower or any Subsidiary is in all material respects of good
and marketable quality, free from material defects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
and each of its Subsidiaries is the sole owner of the Intellectual Property which has any material value that each respectively purports
to own, free and clear of all Liens other than Permitted Liens. Except as noted on the Perfection Certificates (it being understood and
agreed that Borrower and each of its Subsidiaries may from time to time update certain information in the Perfection Certificates after
the Effective Date to the extent permitted by one or more specific provisions in this Agreement; such updated Perfection Certificates
subject to the review and approval of Collateral Agent unless such facts, events or circumstances being updated first arose or occurred
after the Effective Date and do not constitute a breach, default, or Event of Default under this Agreement or any other Loan Document),
neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect
to which Borrower or such Subsidiary is the licensee that (i)&nbsp;prohibits or otherwise restricts Borrower or its Subsidiaries from
granting a security interest in Borrower&rsquo;s or such Subsidiaries&rsquo; interest in such material license or material agreement
or any other property, or (ii)&nbsp;for which a default under or termination of could interfere with Collateral Agent&rsquo;s or any
Lender&rsquo;s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent and each Lender in the then-next
Compliance Certificate (or, within thirty (30) days following the then-next month ending, in the event Compliance Certificates are delivered
less frequently than monthly) following Borrower or any of its Subsidiaries entering into or becoming bound by any material license or
agreement with respect to which Borrower or any Subsidiary is the licensee (other than over-the-counter software that is commercially
available to the public or open source licenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Litigation.
</B>Except as disclosed (i)&nbsp;on the Perfection Certificates, or (ii)&nbsp;in accordance with Section&nbsp;6.9 hereof, there are no
actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or
against Borrower or any of its Subsidiaries that could reasonably be expected to result in damages or costs of more than Five Hundred
Thousand Dollars ($500,000.00) or in which a likely adverse decision would reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Financial
Statements.</B> All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present,
in conformity with GAAP, in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated
results of operations of Borrower and its Subsidiaries (subject, in the case of unaudited financial statements, to normal year-end adjustments
to reflect actual expenses incurred and merger consolidation adjustments and the absence of footnotes and provided further that such
unaudited financial statements shall not include the noncash impact of accounting for stock compensation or other non-cash equity items).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Solvency.
</B>Borrower is, and Borrower and its Subsidiaries, on a consolidated basis, are Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Regulatory
Compliance.</B> Neither Borrower nor any of its Subsidiaries is an &ldquo;investment company&rdquo; or a company &ldquo;controlled&rdquo;
by an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries
is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve
Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards
Act. Neither Borrower nor any of its Subsidiaries is a &ldquo;holding company&rdquo; or an &ldquo;affiliate&rdquo; of a &ldquo;holding
company&rdquo; or a &ldquo;subsidiary company&rdquo; of a &ldquo;holding company&rdquo; as each term is defined and used in the Public
Utility Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any Requirements of Law, the violation
of which could reasonably be expected to have a Material Adverse Change. Neither Borrower&rsquo;s nor any of its Subsidiaries&rsquo;
properties or assets has been used by Borrower or such Subsidiary or, to Borrower&rsquo;s knowledge, by previous Persons, in disposing,
producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower
and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given
all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of Borrower, any of
its Subsidiaries, or, to the knowledge of the Borrower, any of Borrower&rsquo;s or its Subsidiaries&rsquo; controlled Affiliates or any
of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is
(i)&nbsp;in violation of any Anti-Terrorism Law, (ii)&nbsp;engaging in or conspiring to engage in any transaction that evades or avoids,
or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii)&nbsp;is
a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting
or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x)&nbsp;conducts any business or engages
in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y)&nbsp;deals in,
or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No.&nbsp;13224,
any similar executive order or other Anti-Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower and each of its
Subsidiaries has conducted its businesses in compliance with applicable anti-corruption laws (including but not limited to, the United
Kingdom Bribery Act 2010 and the U.S. Foreign Corrupt Practices Act 1977) and has instituted and maintained policies and procedures designed
to promote and achieve compliance with such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Investments.
</B>Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities except for
Permitted Investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Tax
Returns and Payments; Pension Contributions.</B> Borrower and each of its Subsidiaries has timely filed (or timely filed extensions to
file) all required foreign, federal, material state, and material local tax returns and reports, and Borrower and each of its Subsidiaries,
has timely paid all foreign, federal, material state, and material local taxes, assessments, deposits and contributions owed by Borrower
and such Subsidiaries, in all jurisdictions in which Borrower or any such Subsidiary is subject to taxes, including the United States,
unless (a)&nbsp;such taxes are being contested in accordance with the following sentence or (b)&nbsp;if such taxes, assessments, deposits
and contributions owed do not, individually or in the aggregate, exceed Two Hundred Fifty Thousand Dollars ($250,000.00). Borrower and
each of its Subsidiaries, may defer payment of any contested taxes, provided that Borrower or such Subsidiary, (a)&nbsp;in good faith
contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted, (b)&nbsp;notifies
Collateral Agent in writing of the commencement of, and any material development in, the proceedings, and (c)&nbsp;if applicable in the
relevant jurisdiction, post bonds or takes any other steps required to prevent the Governmental Authority levying such contested taxes
from obtaining a Lien upon any of the Collateral that is other than a &ldquo;Permitted Lien.&rdquo; Neither Borrower nor any of its Subsidiaries
is aware of any claims or adjustments proposed for any of Borrower&rsquo;s or such Subsidiaries&rsquo; prior tax years which could result
in additional Taxes in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) becoming due and payable by Borrower or its Subsidiaries.
Neither Borrower nor any of its Subsidiaries is or has at any time been an employer (for the purposes of sections 38 to 51 of the Pensions
Act 2004) of an occupational pension scheme which is not a money purchase scheme (both terms as defined in the Pensions Schemes Act 1993).
Neither Borrower nor any of its Subsidiaries is or has at any time been &ldquo;connected&rdquo; with or an &ldquo;associate&rdquo; of
(as those terms are used in sections 38 and 43 of the Pensions Act 2004) such an employer. Borrower and each of its Subsidiaries have
paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms,
and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination
of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any
liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any
other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Use
of Proceeds.</B> Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business
requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. A
portion of the proceeds of the Term&nbsp;A Loans shall be used by Borrower to repay the Existing Indebtedness in full on the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Shares.
</B></FONT>Borrower has full power and authority to create a first lien on the Shares and no disability or contractual obligation exists
that would prohibit Borrower from pledging the Shares pursuant to this Agreement. To Borrower&rsquo;s knowledge, there are no subscriptions,
warrants, rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares. The
Shares have been and will be duly authorized and validly issued, and are fully paid and non-assessable. To Borrower&rsquo;s knowledge,
the Shares are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower
knows of no reasonable grounds for the institution of any such proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Full
Disclosure.</B> No written representation, warranty or other statement of Borrower or any of its Subsidiaries in any certificate or written
statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together
with all such written certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a
material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading
(it being recognized that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are
not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the
projected or forecasted results).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.12</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>&ldquo;Know
Your Customer&rdquo; Information</B>. All materials and information provided to Collateral Agent and Lenders in connection with applicable
 &ldquo;know your customer&rdquo; and Anti-Terrorism Law are true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Definition
of </B></FONT>&ldquo;<B>Knowledge.</B>&rdquo; For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower&rsquo;s
knowledge or awareness, to the &ldquo;best of&rdquo; Borrower&rsquo;s knowledge, or with a similar qualification, knowledge or awareness
means the actual knowledge, after reasonable investigation, of the Responsible Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>AFFIRMATIVE
COVENANTS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall, and shall
cause each of its Subsidiaries to, do all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Government
Compliance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintain
its and, except as permitted by Section&nbsp;7.3 all its Subsidiaries&rsquo; legal existence and good standing in their respective jurisdictions
of organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have
a Material Adverse Change. Comply with all laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject,
the noncompliance with which could reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Obtain
and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries
of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for
the ratable benefit of the Lenders, in all of the Collateral. Borrower shall promptly provide copies to Collateral Agent of any material
Governmental Approvals obtained by Borrower or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial
Statements, Reports, Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Deliver
to each Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than forty five (45) days after the last day of each quarter, a company prepared consolidated balance
sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such quarter
certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than ninety (90) days after the last day of Borrower&rsquo;s fiscal year, audited consolidated financial
statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent
certified public accounting firm acceptable to Collateral Agent in its reasonable discretion; <U>provided</U> that such unqualified opinion
may include a going concern explanatory paragraph;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available after approval thereof by Borrower&rsquo;s Board of Directors, but no later than thirty (30) days after the last day
of each of Borrower&rsquo;s fiscal years,&nbsp;Borrower&rsquo;s annual financial projections for the entire current fiscal year as approved
by Borrower&rsquo;s Board of Directors, which such annual financial projections shall be set forth in a month-by-month format (such annual
financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the &ldquo;<B>Annual Projections</B>&rdquo;;
provided that, any revisions of the Annual Projections approved by Borrower&rsquo;s Board of Directors shall be delivered to Collateral
Agent and the Lenders no later than seven (7)&nbsp;days after such approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;within
five (5)&nbsp;days of delivery, copies of all written statements, reports and notices made available to Borrower&rsquo;s security holders
of any class of Borrower&rsquo;s securities or holders of Subordinated Debt, in such holders&rsquo; capacities as security holders or
holders of Subordinated Debt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the event that Borrower becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, within five
(5)&nbsp;days of filing, all reports on Form&nbsp;10-K, 10-Q and 8-K filed with the Securities and Exchange Commission,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prompt
notice of any amendments of or other changes to the Operating Documents of Borrower or any of its Subsidiaries, together with any copies
reflecting such amendments or changes with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prompt
notice of any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as available, but no later than thirty (30) days after the last day of each month, copies of the month-end account statements for
each Collateral Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each Lender
by Borrower or directly from the applicable institution(s); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
information as reasonably requested by Collateral Agent or any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, documents required
to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC)
may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such
documents, or provides a link thereto, on Borrower&rsquo;s website on the internet at Borrower&rsquo;s website address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
later than thirty (30) days after the last day of each month, deliver to each Lender, a duly completed Compliance Certificate signed
by a Responsible Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Keep
proper books of record and account in accordance with GAAP in all material respects (subject, in the case of unaudited financial statements,
to normal year-end adjustments to reflect actual expenses incurred and merger consolidation adjustments and the absence of footnotes
and provided further that such unaudited financial statements shall not include the non-cash impact of accounting for stock compensation
or other non-cash equity items), in which full, true and correct entries shall be made of all dealings and transactions in relation to
its business and activities. Borrower shall, and shall cause each of its Subsidiaries to, allow, at the sole cost of Borrower, Collateral
Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an Event
of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from
any of its books and records, and to conduct a collateral audit and analysis of its operations and the Collateral. Such audits shall
be conducted no more often than once every year unless (and more frequently if) an Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Inventory;
Returns.</B> Keep all Inventory held and released for commercial sale in good and marketable condition, free from material defects. Returns
and allowances between Borrower, or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower&rsquo;s, or such
Subsidiary&rsquo;s, customary practices as they exist on the Effective Date in connection with the commercialization of Borrower&rsquo;s
products. Borrower must promptly notify Collateral Agent of all returns, recoveries, disputes and claims that involve more than One Million
Dollars ($1,000,000.00) individually or in the aggregate in any calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Taxes;
Pensions.</B> Timely file and require each of its Subsidiaries to timely file, all required foreign, federal, material state, and material
local tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, material state,
and material local taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, except for deferred payment of
any taxes contested pursuant to the terms of Section&nbsp;5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates
attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans
in accordance with the terms of such plans; provided that, as used herein, &ldquo;material state, and material local Taxes, assessments,
deposits and contributions&rdquo; mean those, individually or in the aggregate, equal to or that exceed Two Hundred Fifty Thousand Dollars
($250,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Insurance.
</B>Keep Borrower&rsquo;s and its Subsidiaries&rsquo; business and the Collateral insured for risks and in amounts standard for companies
in Borrower&rsquo;s and its Subsidiaries&rsquo; industry and location and as Collateral Agent may reasonably request. Insurance policies
shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Collateral Agent hereby agrees
that as of the Effective Date, Borrower&rsquo;s insurance coverage is satisfactory for the purposes herein. All property policies shall
have a lender&rsquo;s loss payable endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral
Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as additional insured. The Collateral Agent
shall be named as lender loss payee and/or additional insured with respect to any such insurance providing coverage in respect of any
Collateral, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent
instruments furnished to the Collateral Agent, that it will give the Collateral Agent twenty (20) days (or, ten (10)&nbsp;days&rsquo;
for non-payment of premiums) prior written notice before any such policy or policies shall be canceled. At Collateral Agent&rsquo;s request,
Borrower shall deliver complete copies of policies and evidence of all premium payments. Proceeds payable under any policy shall, at
Collateral Agent&rsquo;s option, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.
Notwithstanding the foregoing, (a)&nbsp;so long as no Event of Default has occurred and is continuing, Borrower shall have the option
of applying the proceeds of any casualty policy up to Two Hundred Fifty Thousand Dollars ($250,000.00) with respect to any loss, but
not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00), in the aggregate for all losses under all casualty policies in any one
year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (i)&nbsp;shall
be of equal or like value as the replaced or repaired Collateral and (ii)&nbsp;shall be deemed Collateral in which Collateral Agent has
been granted a first priority security interest, subject to Permitted Liens, and (b)&nbsp;after the occurrence and during the continuance
of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral
Agent, for the ratable benefit of the Lenders, on account of the Obligations. If Borrower or any of its Subsidiaries fails to obtain
insurance as required under this Section&nbsp;6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral
Agent may make, at Borrower&rsquo;s expense, all or part of such payment or obtain such insurance policies required in this Section&nbsp;6.5,
and take any action under the policies Collateral Agent deems prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Operating
Accounts.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Maintain
all of Borrower&rsquo;s and its Subsidiaries&rsquo; Collateral Accounts in accounts which are subject to a Control Agreement in favor
of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
shall provide Collateral Agent five (5)&nbsp;days&rsquo; prior written notice before Borrower or any of its Subsidiaries establishes
any Collateral Account. In addition, for each Collateral Account that Borrower or any of its Subsidiaries, at any time maintains, Borrower
or such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to
execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral
Agent&rsquo;s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account,
which Control Agreement may not be terminated without prior written consent of Collateral Agent (but which may be terminated upon the
satisfaction in full in cash of the Obligations (other than inchoate indemnity obligations) and the termination of this Agreement, at
the sole cost and expense of Borrower). The provisions of the previous sentence and Section&nbsp;6.6(a)&nbsp;shall not apply to deposit
accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&rsquo;s,
or any of its Subsidiaries&rsquo;, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates or
by a separate notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with
Sections 6.6(a)&nbsp;and (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protection
of Intellectual Property Rights.</B></FONT> Borrower and each of its Subsidiaries shall: (a)&nbsp;use commercially reasonable efforts
to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower&rsquo;s business;
(b)&nbsp;promptly, after Borrower or any of its Subsidiaries obtains knowledge thereof, advise Collateral Agent in writing of infringement
by a third party of its material Intellectual Property; and (c)&nbsp;not allow any of its Intellectual Property material to Borrower&rsquo;s
business to be abandoned, forfeited or dedicated to the public without Collateral Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Litigation
Cooperation.</B> Commencing on the Effective Date and continuing through the termination of this Agreement, make available to Collateral
Agent and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&rsquo;s officers, employees
and agents and Borrower&rsquo;s Books, to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute
or defend any third-party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or
relating to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices
of Litigation and Default.</B></FONT> Borrower will give prompt written notice to Collateral Agent and the Lenders of any litigation
or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be
expected to result in damages or costs to Borrower or any of its Subsidiaries of Five Hundred Thousand Dollars ($500,000.00) or more
or which could reasonably be expected to have a Material Adverse Change. Without limiting or contradicting any other more specific provision
of this Agreement, promptly (and in any event within five (5)&nbsp;Business Days) upon Borrower becoming aware of the existence of any
Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower
shall give written notice to Collateral Agent and the Lenders of such occurrence, which such notice shall include a reasonably detailed
description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event
of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Intentionally
Omitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Landlord
Waivers; Bailee Waivers.</B></FONT> In the event that Borrower or any of its Subsidiaries, after the Effective Date, intends to add any
new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion
of the Collateral to, a bailee (regardless of whether such office, business location, or warehouse is a new or existing office, business
location or warehouse), in each case pursuant to Section&nbsp;7.2, then Borrower shall provide prior written notice thereof to Collateral
Agent and for any new location in the United States that is the chief executive office of the Borrower or the Collateral at any such
new location is valued in excess of Five Hundred Thousand Dollars ($500,000.00) in the aggregate, Borrower or the applicable Subsidiary
shall use commercially reasonable efforts to cause such bailee or landlord, as applicable, to execute and deliver a bailee waiver or
landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent prior to the addition of any new offices
or business locations, or any such storage with or delivery to any such bailee, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Creation/Acquisition
of Subsidiaries.</B></FONT> In the event Borrower, or any of its Subsidiaries creates or acquires any Subsidiary, Borrower shall provide
prior written notice to Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such action
as may be reasonably required by Collateral Agent or any Lender to cause each such Subsidiary to become a co-Borrower hereunder or to
guarantee the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and security interest in
and to the assets of such Subsidiary (substantially as described on Exhibit&nbsp;A hereto); and Borrower (or its Subsidiary, as applicable)
shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security interest in the Shares of each
such newly created Subsidiary; provided, however, that solely in the circumstance in which Borrower or any Subsidiary creates or acquires
a Foreign Subsidiary in an acquisition permitted by Section&nbsp;7.3 hereof or otherwise approved by the Required Lenders, such Foreign
Subsidiary shall not be required to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents
or grant a continuing pledge and security interest in and to the assets of such Foreign Subsidiary, if (A)&nbsp;Borrower demonstrates
to the reasonable satisfaction of Collateral Agent that such Foreign Subsidiary providing such guarantee or pledge and security interest
would create a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code; (B)&nbsp;no Intellectual
Property is held or maintained by such Foreign Subsidiary that is not a Loan Party at any time; and (C)&nbsp;the aggregate value of cash
and Cash Equivalents held or maintained by such Foreign Subsidiary does not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) at
any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Further
Assurances</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Execute
any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral
Agent&rsquo;s Lien in the Collateral or to effect the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Deliver
to Collateral Agent and Lenders, within five (5)&nbsp;days after the same are sent or received, copies of all material correspondence,
reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect
on any of the Governmental Approvals material to Borrower&rsquo;s business or otherwise could reasonably be expected to have a Material
Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>NEGATIVE
COVENANTS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall not, and shall
not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Dispositions.
</B>Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, &ldquo;Transfer&rdquo;), or permit any of its Subsidiaries
to Transfer, all or any part of its business or property, except for Transfers (a)&nbsp;of Inventory in the ordinary course of business;
(b)&nbsp;of worn out or obsolete Equipment; (c)&nbsp;in connection with Permitted Liens, Permitted Investments and Permitted Licenses;
(d)&nbsp;of cash and Cash Equivalents in connection with transactions not prohibited hereunder in the ordinary course of business; (e)&nbsp;consisting
of the sale or issuance of any stock of Borrower permitted under Section&nbsp;7.2 of this Agreement, (f)&nbsp;consisting of the abandonment,
forfeiture or dedication to the public of any Intellectual Property that is not material to Borrower&rsquo;s business to the extent not
otherwise prohibited by the terms of Section&nbsp;6.7(c); and (g)&nbsp;of other property (other than Intellectual Property) not to exceed
Five Hundred Thousand Dollars ($500,000.00) in the aggregate in any fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Changes
in Business, Management, Ownership, or Business Locations.</B> (a)&nbsp;Engage in or permit any of its Subsidiaries to engage in any
business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto; (b)&nbsp;liquidate
or dissolve except as permitted pursuant to Section&nbsp;7.3; or (c)&nbsp;(i)&nbsp;any Key Person shall cease to be actively engaged
in the management of Borrower unless written notice thereof is provided to Collateral Agent within ten (10)&nbsp;Business Days of such
change, or (ii)&nbsp;consummate any transaction or series of related transactions in which the stockholders of Borrower who were not
stockholders immediately prior to the first such transaction own more than forty nine percent (49%) of the voting stock of Borrower immediately
after giving effect to such transaction or related series of such transactions (other than by the sale of Borrower&rsquo;s equity securities
in a public offering, a private placement of public equity or to venture capital investors so long as Borrower identifies to Collateral
Agent the venture capital investors prior to the closing of the transaction). Borrower shall not, without at least thirty (30) days&rsquo;
prior written notice to Collateral Agent: (A)&nbsp;add any new offices or business locations, including warehouses (unless such new offices
or business locations (i)&nbsp;contain less than Five Hundred Thousand Dollars ($500,000.00) in assets or property of Borrower or any
of its Subsidiaries and (ii)&nbsp;are not Borrower&rsquo;s or its Subsidiaries&rsquo; chief executive office); (B)&nbsp;change its jurisdiction
of organization, (C)&nbsp;change its organizational structure or type, (D)&nbsp;change its legal name, or (E)&nbsp;change any organizational
number (if any) assigned by its jurisdiction of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Mergers
or Acquisitions.</B> Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire,
or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person (including,
without limitation, pursuant to a Division), except for Permitted Acquisitions. A Subsidiary may merge or consolidate into another Subsidiary
(provided such surviving Subsidiary is a &ldquo;co-Borrower&rdquo; hereunder or has provided a secured Guaranty of Borrower&rsquo;s Obligations
hereunder) or with (or into) Borrower provided Borrower is the surviving legal entity, and as long as no Event of Default is occurring
prior thereto or arises as a result therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Indebtedness.
</B>Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Encumbrance.
</B>Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale
of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, subject to Legal Reservations or permit any
Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens that are permitted by
the terms of this Agreement to have priority over Collateral Agent&rsquo;s Lien), or enter into any agreement, document, instrument or
other arrangement (except with or in favor of Collateral Agent, for the ratable benefit of the Lenders) with any Person which directly
or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging,
granting a security interest in or upon, or encumbering any of Borrower&rsquo;s or such Subsidiary&rsquo;s Intellectual Property, except
(a)&nbsp;as is otherwise permitted in Section&nbsp;7.1 hereof and the definition of &ldquo;<B>Permitted Liens</B>&rdquo; herein and (b)&nbsp;for
customary covenants contained in purchase agreements and/or acquisition agreements restricting the granting of security interests on
Borrower&rsquo;s or its Subsidiaries&rsquo; property pending the closing of such transactions; provided that (i)&nbsp;such covenants
do not at any time prohibit the Borrower or such Subsidiaries from granting a security interest in Borrower&rsquo;s or such Subsidiaries&rsquo;
property in favor of Collateral Agent for the benefit of Lenders or in any way impair the Liens in favor of Collateral Agent made in
connection with this Agreement, (ii)&nbsp;the counterparty is not granted a security interest in any property of Borrower or any Subsidiary
and (iii)&nbsp;no Event of Default has occurred and is continuing immediately prior to, nor would occur as a result of, entry into such
purchase agreements and/or acquisition agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Maintenance
of Collateral Accounts.</B> Maintain any Collateral Account except pursuant to the terms of Section&nbsp;6.6 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Distributions;
Investments.</B> (a)&nbsp;Pay any dividends (other than dividends payable solely in capital stock or dividends or other distributions
to a Borrower (and, for the avoidance of doubt, any Subsidiary of a Borrower may pay any dividends or make any other distributions to
a Borrower)) or make any distribution or payment in respect of or redeem, retire or purchase any capital stock (in each case, other than
(i)&nbsp;repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights
plans, director or consultant stock option plans, or similar plans, provided that no Event of Default exists prior to such repurchase
or would not exist after giving effect to such repurchase and (ii)&nbsp;repurchases of stock of former employees, officers, consultants
or directors pursuant to stock repurchase agreements by the cancellation of indebtedness owed by such former employees or directors to
Borrower, provided such repurchases (for both clause (i)&nbsp;and (ii)) do not exceed Five Hundred Thousand Dollars ($500,000.00) in
the aggregate per fiscal year excluding any applicable tax withholding payments) or (b)&nbsp;directly or indirectly make any Investment
other than Permitted Investments, or permit any of its Subsidiaries to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Transactions
with Affiliates.</B> Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or
any of its Subsidiaries, except for (a)&nbsp;transactions that are in the ordinary course of Borrower&rsquo;s or such Subsidiary&rsquo;s
business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an arm&rsquo;s
length transaction with a non-affiliated Person, (b)&nbsp;transaction explicitly permitted or required to be made hereunder between Affiliates,
(c)&nbsp;compensation related arrangements in the ordinary course of business or otherwise approved by Borrower&rsquo;s board or by the
Required Lenders in writing, and (e)&nbsp;Subordinated Debt or equity investments by Borrower&rsquo;s investors in Borrower or its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Subordinated
Debt.</B> (a)&nbsp;Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or
other similar agreement to which such Subordinated Debt is subject, or (b)&nbsp;amend any provision in any document relating to the Subordinated
Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Compliance.
</B>Become an &ldquo;investment company&rdquo; or a company controlled by an &ldquo;investment company&rdquo;, under the Investment Company
Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined
in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose;
fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to
occur; fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation could reasonably
be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so; be or become an employer (for the purposes
of sections 38 to 51 of the Pensions Act 2004) of an occupational pension scheme which is not a money purchase scheme (both terms as
defined in the Pensions Schemes Act 1993). or &ldquo;connected&rdquo; with or an &ldquo;associate&rdquo; of (as those terms are used
in sections 38 and 43 of the Pensions Act 2004) such an employer; withdraw or permit any Subsidiary to withdraw from participation in,
permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing
and deferred compensation plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries,
including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower and each of its Subsidiaries shall not
directly or indirectly use the proceeds of the Loans for any purpose which would breach the Bribery Act 2010, the United States Foreign
Corrupt Practices Act of 1977 or other similar legislation in other jurisdictions. Borrower and each of its Subsidiaries shall conduct
its businesses in compliance with applicable anti-corruption laws (including but not limited to, the United Kingdom Bribery Act 2010
and the U.S. Foreign Corrupt Practices Act 1977) and maintain policies and procedures designed to promote and achieve compliance with
such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Compliance
with Anti-Terrorism Laws.</B> Collateral Agent hereby notifies Borrower and each of its Subsidiaries that pursuant to the requirements
of Anti-Terrorism Laws, and Collateral Agent&rsquo;s policies and practices, Collateral Agent is required to obtain, verify and record
certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which information includes
the name and address of Borrower and each of its Subsidiaries and their principals and such other information that will allow Collateral
Agent to identify such party in accordance with Anti-Terrorism Laws. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower
or any of its Subsidiaries permit any controlled Affiliate to, directly or indirectly, knowingly enter into any documents, instruments,
agreements or contracts with any Person listed on the OFAC Lists or similar lists produced by an Authority. Borrower and each of its
Subsidiaries shall immediately notify Collateral Agent if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary
or controlled Affiliate of Borrower, is listed on the OFAC Lists or similar lists produced by an Authority or (a)&nbsp;is convicted on,
(b)&nbsp;pleads <I>nolo contendere</I> to, (c)&nbsp;is indicted on, or (d)&nbsp;is arraigned and held over on charges involving money
laundering or predicate crimes to money laundering. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of
its Subsidiaries, permit any controlled Affiliate to, directly or indirectly, (i)&nbsp;conduct any business or engage in any transaction
or dealing with any Blocked Person, or in any Sanctioned Country including, without limitation, the making or receiving of any contribution
of funds, goods or services to or for the benefit of any Blocked Person, (ii)&nbsp;deal in, or otherwise engage in any transaction relating
to, any property or interests in property blocked pursuant to Executive Order No.&nbsp;13224 or any similar executive order or other
Anti-Terrorism Laws, or (iii)&nbsp;engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading
or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No.&nbsp;13224 or other Anti-Terrorism Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>EVENTS
OF DEFAULT</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any one of the following
shall constitute an event of default (an &ldquo;<B>Event of Default</B>&rdquo;) under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Payment
Default.</B> Borrower fails to (a)&nbsp;make any payment of principal or interest on any Credit Extension on its due date, or (b)&nbsp;pay
any other Obligations within three (3)&nbsp;Business Days after such Obligations are due and payable (which three (3)&nbsp;Business Day
grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section&nbsp;9.1 (a)&nbsp;hereof).
During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during
the cure period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
Default.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates),
6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and
Default), 6.12 (Creation/Acquisition of Subsidiaries) or 6.13 (Further Assurances) or Borrower violates any covenant in Section&nbsp;7;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower,
or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement
contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section&nbsp;8) under such
other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within ten (10)&nbsp;days after
the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the ten (10)&nbsp;day period or cannot
after diligent attempts by Borrower be cured within such ten (10)&nbsp;day period, and such default is likely to be cured within a reasonable
time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default,
and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions
shall be made during such cure period). Grace periods provided under this Section&nbsp;shall not apply, among other things, to financial
covenants or any other covenants set forth in subsection (a)&nbsp;above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Material
Adverse Change.</B> A Material Adverse Change occurs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Attachment;
Levy; Restraint on Business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;The
service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity
under control of Borrower or its Subsidiaries on deposit with any Lender or any Lender&rsquo;s Affiliate or any bank or other institution
at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii)&nbsp;a notice of lien, levy, or assessment is filed
against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i)&nbsp;and
(ii)&nbsp;hereof are not, within ten (10)&nbsp;days after the occurrence thereof, discharged or stayed (whether through the posting of
a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10)&nbsp;day cure period; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;any
material portion of Borrower&rsquo;s or any of its Subsidiaries&rsquo; assets is attached, seized, levied on, or comes into possession
of a trustee or receiver, or (ii)&nbsp;any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting
any material part of its business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Insolvency.
</B>(a)&nbsp;Borrower is or becomes Insolvent, or Borrower and its Subsidiaries, taken as a whole, are or become Insolvent; (b)&nbsp;Borrower
or any of its Subsidiaries begins an Insolvency Proceeding; or (c)&nbsp;an Insolvency Proceeding is begun against Borrower or any of
its Subsidiaries and not dismissed or stayed within forty-five (45) days (but no Credit Extensions shall be made while Borrower or any
Subsidiary is Insolvent and/or until any Insolvency Proceeding is dismissed);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Other
Agreements.</B> There is a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or parties
resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount
in excess of Five Hundred Thousand Dollars ($500,000.00) or that could reasonably be expected to have a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Judgments.
</B>One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least Five
Hundred Thousand Dollars ($500,000.00) (not covered by independent third-party insurance as to which liability has been accepted by such
insurance carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated, or unstayed
for a period of ten (10)&nbsp;days after the entry thereof (provided that no Credit Extensions will be made prior to the satisfaction,
vacation, or stay of such judgment, order or decree);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Misrepresentations.
</B>Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty,
or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or
to induce Collateral Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other
statement is incorrect in any material respect when made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Subordinated
Debt.</B> A default or breach occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of Borrower or
any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders,
or any creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any material terms of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Guaranty.
</B></FONT>(a)&nbsp;Any Guaranty terminates or ceases for any reason to be in full force and effect; (b)&nbsp;any Guarantor does not
perform any obligation or covenant under any Guaranty; (c)&nbsp;any circumstance described in Section&nbsp;8.3, 8.4, 8.5, 8.7, or 8.8
occurs with respect to any Guarantor, or (d)&nbsp;the liquidation, winding up, or termination of existence of any Guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Governmental
Approvals.</B> Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner, or not renewed
in the ordinary course for a full term <I>and</I> such revocation, rescission, suspension, modification or non-renewal has resulted in
or would reasonably be expected to result in a Material Adverse Change; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Lien
Priority</B>. Any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien
on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens which are permitted
to have priority in accordance with the terms of this Agreement; provided that such circumstance is not due to Collateral Agent&rsquo;s
failure to file an appropriate continuation financing statement, amendment financing statement or initial financing statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Delisting</B></FONT>.
The American Depository Shares of Parent are delisted from Nasdaq Global Market because of failure to comply with continued listing standards
thereof or due to a voluntary delisting, in each case, which results in such shares and the ordinary shares of Parent not being listed
on any nationally recognized stock exchange in the United States having listing standards at least as restrictive as the Nasdaq Global
Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>RIGHTS
AND REMEDIES</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Rights
and Remedies</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the occurrence and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required Lenders
shall, without notice or demand, do any or all of the following: (i)&nbsp;deliver notice of the Event of Default to Borrower, (ii)&nbsp;by
notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section&nbsp;8.5 occurs
all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii)&nbsp;by notice to
Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower&rsquo;s benefit
under this Agreement or under any other agreement between Borrower and Collateral Agent and/or the Lenders (but if an Event of Default
described in Section&nbsp;8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower&rsquo;s benefit
under this Agreement or under any other agreement between Borrower and Collateral Agent and/or the Lenders shall be immediately terminated
without any action by Collateral Agent or the Lenders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the rights of Collateral Agent and the Lenders set forth in Section&nbsp;9.1(a)&nbsp;above, upon the occurrence and during the
continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;foreclose
upon and/or sell or otherwise liquidate, the Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;apply
to the Obligations any (a)&nbsp;balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or (b)&nbsp;any
amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;commence
and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a)&nbsp;and (b)&nbsp;above, upon the occurrence and
during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;settle
or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable,
notify any Person owing Borrower money of Collateral Agent&rsquo;s security interest in such funds, and verify the amount of such account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make
any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.
Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably
designates. Collateral Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral,
and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses
incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral
Agent&rsquo;s rights or remedies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral. Collateral Agent is hereby
granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower&rsquo;s and each of its Subsidiaries&rsquo;
labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising
matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any
Collateral and, in connection with Collateral Agent&rsquo;s exercise of its rights under this Section&nbsp;9.1, Borrower&rsquo;s and
each of its Subsidiaries&rsquo; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of
the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;place
a &ldquo;hold&rdquo; on any account maintained with Collateral Agent or the Lenders and/or deliver a notice of exclusive control, any
entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any
Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;demand
and receive possession of Borrower&rsquo;s Books;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;appoint
a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent
court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower
or any of its Subsidiaries; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;subject
to clauses 9.1(a)&nbsp;and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents
or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Section&nbsp;9.1
to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies
referenced in this Section&nbsp;9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.
As used in the immediately preceding sentence, &ldquo;<B>Exigent Circumstance</B>&rdquo; means any event or circumstance that, in the
reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion
of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste
thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or reinstate adequate casualty insurance
coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of
the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Power
of Attorney.</B></FONT> Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable solely upon
the occurrence and during the continuance of an Event of Default, to: (a)&nbsp;endorse Borrower&rsquo;s or any of its Subsidiaries&rsquo;
name on any checks or other forms of payment or security; (b)&nbsp;sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any
invoice or bill of lading for any Account or drafts against Account Debtors; (c)&nbsp;settle and adjust disputes and claims about the
Accounts directly with Account Debtors, for amounts and on terms Collateral Agent determines reasonable; (d)&nbsp;make, settle, and adjust
all claims under Borrower&rsquo;s insurance policies; (e)&nbsp;pay, contest or settle any Lien, charge, encumbrance, security interest,
and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the
same; and (f)&nbsp;transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits.
Borrower hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name
on any documents necessary to perfect or continue the perfection of Collateral Agent&rsquo;s security interest in the Collateral regardless
of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations) have been satisfied in
full and the Lenders are under no further obligation to make Credit Extensions hereunder. Collateral Agent&rsquo;s foregoing appointment
as Borrower&rsquo;s or any of its Subsidiaries&rsquo; attorney in fact, and all of Collateral Agent&rsquo;s rights and powers, coupled
with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations) have been fully repaid and performed
and the Lenders&rsquo; obligation to provide Credit Extensions terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Protective
Payments.</B></FONT> If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section&nbsp;6.5 or fails to pay
any premium thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement
or any other Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent
are Lenders&rsquo; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral
Agent will make reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment
at the time it is obtained or paid or within a reasonable time thereafter. No such payments by Collateral Agent are deemed an agreement
to make similar payments in the future or Collateral Agent&rsquo;s waiver of any Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Application
of Payments and Proceeds.</B></FONT> Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during
the continuance of an Event of Default, (a)&nbsp;Borrower irrevocably waives the right to direct the application of any and all payments
at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part
of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have
the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral
Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b)&nbsp;the proceeds of any sale of, or other
realization upon all or any part of the Collateral shall be applied: first, to the Lenders&rsquo; Expenses; second, to accrued and unpaid
interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code or the Insolvency
Act, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness
or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered
to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying
out the foregoing, (x)&nbsp;amounts received shall be applied in the numerical order provided until exhausted prior to the application
to the next succeeding category, and (y)&nbsp;each of the Persons entitled to receive a payment in any particular category shall receive
an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement
to an allocation between or sharing by the Lenders of any right, interest or obligation &ldquo;ratably,&rdquo; &ldquo;proportionally&rdquo;
or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender,
shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&rsquo;s portion
of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing,
a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled
payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments
made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure
the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character,
whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment
or distribution in excess of such Lender&rsquo;s ratable share shall be received by such Lender in trust for and shall be promptly paid
over to the other Lender for application to the payments of amounts due on the other Lenders&rsquo; claims. To the extent any payment
for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another
as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral,
it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral
Agent&rsquo;s security interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liability
for Collateral.</B></FONT> So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping
of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall
not be liable or responsible for: (a)&nbsp;the safekeeping of the Collateral; (b)&nbsp;any loss or damage to the Collateral; (c)&nbsp;any
diminution in the value of the Collateral; or (d)&nbsp;any act or default of any carrier, warehouseman, bailee, or other Person. Borrower
bears all risk of loss, damage or destruction of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Waiver; Remedies Cumulative.</B></FONT> Failure by Collateral Agent or any Lender, at any time or times, to require strict performance
by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral
Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective
unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which
it is given. The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative.
Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity. The
exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent&rsquo;s or any Lender&rsquo;s
waiver of any Event of Default is not a continuing waiver. Collateral Agent&rsquo;s or any Lender&rsquo;s delay in exercising any remedy
is not a waiver, election, or acquiescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Demand
Waiver.</B></FONT> Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment
and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents,
instruments, chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>NOTICES</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, consents, requests,
approvals, demands, or other communication (collectively, &ldquo;<B>Communication</B>&rdquo;) by any party to this Agreement or any other
Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a)&nbsp;upon the earlier of actual
receipt and three (3)&nbsp;Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested,
with proper postage prepaid; (b)&nbsp;upon transmission, when sent by facsimile or electronic mail transmission; (c)&nbsp;one (1)&nbsp;Business
Day after deposit with a reputable overnight courier with all charges prepaid; or (d)&nbsp;when delivered, if hand-delivered by messenger,
all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.
Any of Collateral Agent, Lender or Borrower may change its mailing address, facsimile number, or email address by giving the other party
written notice thereof in accordance with the terms of this Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 35%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Borrower:</FONT></TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 63%"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">VERONA PHARMA PLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">VERONA PHARMA,&nbsp;INC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">3 More London Riverside</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">London, SE1 2RE, UK</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: David Zaccardelli, Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: Claire Poll, General Counsel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: [***]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: left; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not
    constitute notice) to:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Latham&nbsp;&amp; Watkins, LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">505 Montgomery Street, Suite&nbsp;2000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">San Francisco, CA 94111</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: Dan Van Fleet</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: Dan.VanFleet@lw.com</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If to Collateral Agent:</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">OXFORD FINANCE LUXEMBOURG S.&Agrave;<BR>
    R.L., acting for and on behalf of its Compartment 7<BR>
    <BR>
    2, route d&rsquo;Arlon,<BR>
    L-8008 Strassen,<BR>
    Grand Duchy of Luxembourg<BR>
    Fax: [***]<BR>
    Email: [***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">with a copy to:</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">OXFORD FINANCE LLC 115<BR>
    South Union Street<BR>
    Suite&nbsp;300<BR>
    Alexandria, VA&nbsp; 22314<BR>
    Attention: Legal Department<BR>
    Fax: [***]<BR>
    Email: [***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not
    constitute notice) to:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Greenberg Traurig, LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">One International Place</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Boston, MA 02110</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: Abdullah Malik</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Fax: (617) 897-0983</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    </FONT>malikab@gtlaw.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>CHOICE
OF LAW, VENUE AND JURY TRIAL WAIVER</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York law governs the Loan Documents without
regard to principles of conflicts of law. Borrower, Lenders and Collateral Agent each submit to the exclusive jurisdiction of the State
and Federal courts in the City of New York, Borough of Manhattan. NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND THE LENDERS SHALL
HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL
AGENT AND THE LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION&nbsp;9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL
OR TO OTHERWISE ENFORCE COLLATERAL AGENT&rsquo;S AND THE LENDERS&rsquo; RIGHTS AGAINST BORROWER OR ITS PROPERTY. Borrower expressly submits
and consents in advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby waives any objection
that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting
of such legal or equitable relief as is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints,
and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by
registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with,
Section&nbsp;10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower&rsquo;s actual
receipt thereof or three (3)&nbsp;days after deposit in the U.S. mails, first class, registered or certified mail return receipt requested,
proper postage prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, BORROWER, COLLATERAL AGENT, AND THE LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF
OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION,&nbsp;INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL
OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR EACH PARTY TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH
ITS COUNSEL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>GENERAL
PROVISIONS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Successors
and Assigns.</B></FONT> This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may
not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&rsquo;s and each Lender&rsquo;s
prior written consent (which may be granted or withheld in Collateral Agent&rsquo;s and each Lender&rsquo;s discretion, subject to Section&nbsp;12.6).
The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation
in <B>(any </B>such sale, transfer, assignment, negotiation<B>,</B> or grant of a participation, a <B>&ldquo;Lender Transfer&rdquo;)
</B>all or any part of, or any interest in, the Lenders&rsquo; obligations, rights, and benefits under this Agreement and the other Loan
Documents; <I>provided</I>, <I>however</I>, that any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible
Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written
consent of the Required Lenders (such approved assignee, an &ldquo;<B>Approved Lender</B>&rdquo;)<B>.</B> Borrower and Collateral Agent
shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral
Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered
and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee
or Approved Lender as Collateral Agent reasonably shall require. Notwithstanding anything to the contrary contained herein, so long as
no Event of Default has occurred and is continuing, no Lender Transfer (other than a Lender Transfer in connection with (x)&nbsp;assignments
by a Lender due to a forced divestiture at the request of any regulatory agency; or (y)&nbsp;upon the occurrence of a default, event
of default or similar occurrence with respect to a Lender&rsquo;s own financing or securitization transactions) shall be permitted, without
Borrower&rsquo;s consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture
hedge fund, each as determined by Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Indemnification.
</B>Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors, officers, employees,
agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &ldquo;<B>Indemnified
Person</B>&rdquo;) harmless against: (a)&nbsp;all obligations, demands, claims, and liabilities (collectively, &ldquo;<B>Claims</B>&rdquo;)
asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated
by the Loan Documents; and (b)&nbsp;all losses or Lenders&rsquo; Expenses incurred, or paid by Indemnified Person in connection with;
related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral Agent,
and/or the Lenders and Borrower (including reasonable and documented attorneys&rsquo; fees and expenses), except for Claims and/or losses
directly caused by such Indemnified Person&rsquo;s gross negligence or willful misconduct. Borrower hereby further indemnifies, defends
and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented
fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative
or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding
initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar
technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent
or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted
against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use
of the proceeds of the loan provided hereunder, in each case except for liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs, expenses and disbursements directly caused by such Indemnified Person&rsquo;s gross negligence or willful
misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Time
of Essence.</B> Time is of the essence for the performance of all Obligations in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Severability
of Provisions.</B> Each provision of this Agreement is severable from every other provision in determining the enforceability of any
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Correction
of Loan Documents.</B></FONT> Collateral Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and
the other Loan Documents consistent with the agreement of the parties so long as Collateral Agent provides Borrower with written notice
of such correction and allows Borrower at least ten (10)&nbsp;days to object to such correction. In the event of such objection, such
correction shall not be made except by an amendment signed by Collateral Agent, the Lenders and Borrower<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Amendments
in Writing; Integration.</B> (a)&nbsp;No amendment, modification, termination or waiver of any provision of this Agreement or any other
Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall
in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&rsquo;s Term Loan Commitment
or Commitment Percentage shall be effective as to such Lender without such Lender&rsquo;s written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral
Agent&rsquo;s written consent or signature;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A)&nbsp;reduce the principal
of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or
fees (other than late charges) with respect to any Term Loan (B)&nbsp;postpone the date fixed for, or waive, any payment of principal
of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges
or for any termination of any commitment); (C)&nbsp;change the definition of the term &ldquo;<B>Required Lenders</B>&rdquo; or the percentage
of Lenders which shall be required for the Lenders to take any action hereunder; (D)&nbsp;release all or substantially all of any material
portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the
Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except,
in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents
(including in connection with any disposition permitted under this Agreement); (E)&nbsp;amend, waive or otherwise modify this Section&nbsp;12.6
or the definitions of the terms used in this Section&nbsp;12.6 insofar as the definitions affect the substance of this Section&nbsp;12.6;
(F)&nbsp;consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document
or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant
to a merger or consolidation permitted pursuant to this Agreement; (G)&nbsp;amend any of the provisions of Section&nbsp;9.4 or amend
any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their
Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H)&nbsp;subordinate the Liens granted in favor of
Collateral Agent securing the Obligations; or (I)&nbsp;amend any of the provisions of Section&nbsp;12.10. It is hereby understood and
agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the
preceding clauses (C), (D), (E), (F), (G)&nbsp;and (H)&nbsp;of the preceding sentence;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
provisions of the foregoing clauses (i), (ii)&nbsp;and (iii)&nbsp;are subject to the provisions of any interlender or agency agreement
among the Lenders and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver
or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Other
than as&nbsp;expressly provided for in Section&nbsp;12.6(a)(i)-(iii), Collateral Agent may, if requested by the Required Lenders, from
time to time&nbsp;designate covenants in this Agreement less restrictive by notification to a Responsible Officer of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.
All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this
Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Counterparts.
</B>This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when
executed and delivered, is an original, and all taken together, constitute one Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Survival.
</B>All covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated
pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms,
are to survive the termination of this Agreement) have been satisfied. The obligation of Borrower in Section&nbsp;12.2 to indemnify each
Lender and Collateral Agent, as well as the confidentiality provisions in Section&nbsp;12.9 below, shall survive until the statute of
limitations with respect to such claim or cause of action shall have run.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Confidentiality</B></FONT><B>.
</B>In handling any confidential information of Borrower or any of its Subsidiaries, the Lenders and Collateral Agent shall exercise
the same degree of care that it exercises for their own proprietary information, but disclosure of information may be made: (a)&nbsp;subject
to the terms and conditions of this Agreement, to the Lenders&rsquo; and Collateral Agent&rsquo;s Subsidiaries or Affiliates that are
subject to confidentiality provisions of this Section&nbsp;12.9, or in connection with a Lender&rsquo;s own financing or securitization
transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization
transaction; (b)&nbsp;to prospective transferees (other than those identified in (a)&nbsp;above) or purchasers of any interest in the
Credit Extensions (provided, however, the Lenders and Collateral Agent shall, except upon the occurrence and during the continuance of
an Event of Default, obtain such prospective transferee&rsquo;s or purchaser&rsquo;s agreement to the terms of this provision or to similar
confidentiality terms); (c)&nbsp;as required by law, regulation, subpoena, or other order; (d)&nbsp;to Lenders&rsquo; or Collateral Agent&rsquo;s
regulators or as otherwise required in connection with an examination or audit; (e)&nbsp;as Collateral Agent reasonably considers appropriate
in exercising remedies under the Loan Documents; and (f)&nbsp;to third party service providers of the Lenders and/or Collateral Agent
so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less
restrictive than those contained herein. Confidential information does not include information that either: (i)&nbsp;is in the public
domain or in the Lenders&rsquo; and/or Collateral Agent&rsquo;s possession when disclosed to the Lenders and/or Collateral Agent, or
becomes part of the public domain after disclosure to the Lenders and/or Collateral Agent (other than as a result of its disclosure by
Collateral Agent or any Lender in violation of this Agreement); or (ii)&nbsp;is disclosed to the Lenders and/or Collateral Agent by a
third party, if the Lenders and/or Collateral Agent does not know that the third party is prohibited from disclosing the information.
Collateral Agent and the Lenders may use confidential information for any purpose, including, without limitation, for the development
of client databases, reporting purposes, and market analysis so long as Collateral Agent and the Lenders do not disclose Borrower&rsquo;s
identity or the identity of any person associated with Borrower unless otherwise expressly permitted by this Agreement. The provisions
of the immediately preceding sentence shall survive the termination of this Agreement. The agreements provided under this Section&nbsp;12.9
supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter
of this Section&nbsp;12.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Public
Announcement.</B> Notwithstanding anything else herein to the contrary, Borrower hereby agrees that Collateral Agent and each Lender
may make a public announcement of the transactions contemplated by this Agreement, and may publicize the same on its company website,
in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower&rsquo;s name,
tradenames, logos, and any information related to the transactions to the extent such information is not confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Right
of Set Off.</B> Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set off as security
for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits,
credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent or the Lenders
or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them.
At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the
Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured
and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE
ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH
RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Cooperation
of Borrower.</B></FONT> If necessary, Borrower agrees to (i)&nbsp;execute any documents (including new Secured Promissory Notes) reasonably
required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section&nbsp;12.1,
(ii)&nbsp;make Borrower&rsquo;s management available to meet with Collateral Agent and prospective participants and assignees of Term
Loan Commitments or Credit Extensions (which meetings shall be conducted no more often than twice every twelve months unless an Event
of Default has occurred and is continuing), and (iii)&nbsp;assist Collateral Agent or the Lenders in the preparation of information relating
to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may
request. Subject to the provisions of Section&nbsp;12.9, Borrower authorizes each Lender to disclose to any prospective participant or
assignee of a Term Loan Commitment, any and all information in such Lender&rsquo;s possession concerning Borrower and its financial affairs
which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender
by or on behalf of Borrower in connection with such Lender&rsquo;s credit evaluation of Borrower prior to entering into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
Liability</B></FONT>. Either Borrower may, acting singly, request Credit Extensions hereunder. Each Borrower hereby appoints the other
as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder. Each Borrower hereunder
shall be jointly and severally obligated to repay all Credit Extensions made hereunder, regardless of which Borrower actually receives
said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions. Each Borrower waives (a)&nbsp;any suretyship
defenses available to it under the Code or any other applicable law, and (b)&nbsp;any right to require Collateral Agent or any Lender
to: (i)&nbsp;proceed against any Borrower or any other person; (ii)&nbsp;proceed against or exhaust any security; or (iii)&nbsp;pursue
any other remedy. Collateral Agent and or any Lender may exercise or not exercise any right or remedy it has against any Borrower or
any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&rsquo;s liability.
Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it
may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and the Lenders
under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other
Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to
the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in,
any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this
Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section&nbsp;shall
be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust
for Collateral Agent and the Lenders and such payment shall be promptly delivered to Collateral Agent for application to the Obligations,
whether matured or unmatured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Electronic
Execution of Documents</B></FONT>. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature&rdquo; and words of like
import in any Loan Document shall be deemed to include electronic signatures, or the keeping of records in electronic form, each of which
shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping
systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based
on the Uniform Electronic Transactions Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Limited
Recourse and Non-Petition. </B></FONT>Each party acknowledges and accepts that in relation to its claims against any Lender that is a
Luxembourg securitisation vehicle (&ldquo;<B>Lux SV</B>&rdquo;) acting in respect of a specific compartment (the &ldquo;<B>Relevant Compartment</B>&rdquo;),
it will only have recourse to the assets of the Relevant Compartment and not to the assets of any other compartments of such Lux SV or
any other assets of the Lux SV and any claim by any and all Parties against such Lender will be reduced to the extent that the total
of such claims exceeds the aggregate value of the net assets of the Relevant Compartment remaining after meeting prior ranking claims
secured thereon and that no Party is entitled to take any steps against the Lux SV to recover any further amounts due and the right to
receive any such further amounts shall be extinguished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither any party nor any
Person acting on its behalf will be entitled to petition or take any other step for the administration, bankruptcy, reorganisation, arrangement,
insolvency, composition with creditors, reprieve from payment, controlled management, liquidation, winding-up or other similar actions
under any applicable law of the Lux SV (other than the Relevant Compartment), nor will any of them have any claim in respect of any sum
arising in respect of any assets of the Lux SV not forming part of the Relevant Compartment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>DEFINITIONS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Definitions.
</B>As used in this Agreement, the following terms have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>1-Month CME Term
SOFR</B>&rdquo; is the 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&rsquo;s
Website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Account</B>&rdquo;
is any &ldquo;account&rdquo; as defined in the Code with such additions to such term as may hereafter be made, and includes, without
limitation, all accounts receivable and other sums owing to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Account Debtor</B>&rdquo;
is any &ldquo;account debtor&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is
under common control with the Person, and each of that Person&rsquo;s senior executive officers, directors, partners and, for any Person
that is a limited liability company, that Person&rsquo;s managers and members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>AML/CTF Law</B>&rdquo;
is the Luxembourg law of 12 November&nbsp;2004 on the fight against money laundering and terrorist financing, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amortization Date</B>&rdquo;
is, (i)&nbsp;December&nbsp;1, 2025, if the Term D Loans are not made and (ii)&nbsp;December&nbsp;1, 2026, if the Term D Loans are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Annual Projections</B>&rdquo;
is defined in Section&nbsp;6.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><B>Anti-Terrorism
Laws</B>&rdquo; are any laws relating to terrorism or money laundering, including Executive Order No.&nbsp;13224 (effective September&nbsp;24,
2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, the laws administered by OFAC and the AML/CTF Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Approved Fund</B>&rdquo;
is any (a)&nbsp;Person, investment company, fund, securitization vehicle or conduit that is (or will be) engaged in making, purchasing,
holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business and that is
administered or managed by (i)&nbsp;a Lender, (ii)&nbsp;an Affiliate of a Lender, or (iii)&nbsp;a Person (other than a natural person)
or an Affiliate of a Person (other than a natural person) that administers or manages a Lender, or (b)&nbsp;any Person (other than a
natural person) which temporarily warehouses loans, or provides financing or securitizations, in each case, for any Lender&nbsp;or any
entity described in the preceding clause (a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Approved Lender</B>&rdquo;
is defined in Section&nbsp;12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Authority</B>&rdquo;
is any relevant government agency or legislature in the United States, the European Union or any of its member states or other relevant
jurisdiction, including OFAC, the U.S. State Department, the United Nations Security Commission, the CSSF and the Commission of the European
Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Basic Rate</B>&rdquo;
is with respect to each Term Loan, the per annum rate of interest (based on a year of three hundred sixty (360) days) equal to (a)&nbsp;the
greater of (i)&nbsp;the 1-Month CME Term SOFR on the last Business Day of the month that immediately precedes the month in which the
interest will accrue and (ii)&nbsp;two and thirty-eight hundredths percent (2.38%), plus (b)&nbsp;five and fifty hundredths percent (5.50%).
Notwithstanding the foregoing, (i)&nbsp;in no event shall the Basic Rate (x)&nbsp;for the Term A Loan be less than seven and eighty-eight
hundredths percent (7.88%) and (y)&nbsp;for each other Term Loan be less than the Basic Rate on the Business Day immediately prior to
the Funding Date of such Term Loan, (ii)&nbsp;upon the occurrence of a Benchmark Transition Event, Collateral Agent may, in good faith
and with reference to the margin above such interest rate in this definition, amend this Agreement in good faith to replace the Benchmark
with a replacement interest rate and replacement margin above such interest rate that results in a substantially similar interest rate
floor and total rate in effect immediately prior to the effectiveness of such replacement interest rate and replacement margin, and any
such amendment shall become effective at 5:00 p.m.&nbsp;Eastern time on the third Business Day after Collateral Agent has notified Borrower
of such amendment, (iii)&nbsp;the Basic Rate for the Term A Loan for the period from the Effective Date through and including October&nbsp;31,
2022 shall be 8.54205% and (iv)&nbsp; the Basic Rate for each Term Loan shall not increase by more than two hundred basis points (2.00%)
above the applicable Basic Rate as of the Funding Date of each such Term Loan. Any determination, decision or election that may be made
by Collateral Agent pursuant hereto will be conclusive and binding absent manifest error and may be made in Collateral Agent&rsquo;s
sole discretion and without consent from any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark</B>&rdquo;
is, initially, the 1-Month CME Term SOFR; provided, that if a Benchmark Transition Event has occurred with respect to the 1-Month CME
Term SOFR or the then-current Benchmark, then &ldquo;Benchmark&rdquo; means the applicable replacement rate that has replaced the immediately
preceding benchmark rate pursuant to the defined term &ldquo;Basic Rate&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benchmark Transition
Event</B>&rdquo; means the occurrence of one or more of the following events with respect to the then-current Benchmark:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
public statement or publication of information by or on behalf of the administrator for such Benchmark announcing that such Person has
ceased or will cease to provide such Benchmark, permanently or indefinitely, provided that, at the time of such statement or publication,
there is no successor administrator that will continue to provide such Benchmark;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
public statement or publication of information by the regulatory supervisor for the administrator for such Benchmark, the U.S. Federal
Reserve System, an insolvency official with jurisdiction over the administrator for such Benchmark, a resolution authority with jurisdiction
over the administrator for such Benchmark or a court or an entity with similar insolvency or resolution authority over the administrator
for such Benchmark, which states that the administrator for such Benchmark has ceased or will cease to provide such Benchmark permanently
or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue
to provide such Benchmark; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
public statement or publication of information by the regulatory supervisor for the administrator for such Benchmark announcing that
such Benchmark is no longer representative or in compliance with the International Organization of Securities Commissions Principles
for Financial Benchmarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Blocked
Person</B>&rdquo;</FONT> is any Person: (a)&nbsp;listed in the annex to, or is otherwise subject to the provisions of, Executive Order
No.&nbsp;13224, (b)&nbsp;a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or
is otherwise subject to the provisions of, Executive Order No.&nbsp;13224, (c)&nbsp;a Person with which any Lender is prohibited from
dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d)&nbsp;a Person that commits, threatens or conspires to
commit or supports &ldquo;terrorism&rdquo; as defined in Executive Order No.&nbsp;13224, or (e)&nbsp;a Person that is named a &ldquo;specially
designated national&rdquo; or &ldquo;blocked person&rdquo; on the most current list published by OFAC or other similar list, (f)&nbsp;named
on the EU Consolidated Financial Sanctions List and any similar list, each as amended, supplemented or substituted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrower</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrower&rsquo;s
Books</B>&rdquo; are Borrower&rsquo;s or any of its Subsidiaries&rsquo; books and records including ledgers, federal, and state tax returns,
records regarding Borrower&rsquo;s or its Subsidiaries&rsquo; assets or liabilities, the Collateral, business operations or financial
condition, and all computer programs or storage or any equipment containing such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Cash
Equivalents</B>&rdquo;</FONT> are (a)&nbsp;marketable direct obligations issued or unconditionally guaranteed by the United States or
any agency or any State thereof having maturities of not more than one (1)&nbsp;year from the date of acquisition; (b)&nbsp;commercial
paper maturing no more than one (1)&nbsp;year after its creation and having the highest rating from either Standard&nbsp;&amp; Poor&rsquo;s
Ratings Group or Moody&rsquo;s Investors Service,&nbsp;Inc., (c)&nbsp;certificates of deposit maturing no more than one (1)&nbsp;year
after issue provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement in favor
of Collateral Agent and (d)&nbsp;money market funds at least 95% of which constitute Cash Equivalents of the kinds described in clauses
(a)&nbsp;through (c)&nbsp;herein. For the avoidance of doubt, the direct purchase by Borrower or any of its Subsidiaries of any Auction
Rate Securities, or purchasing participations in, or entering into any type of swap or other derivative transaction, or otherwise holding
or engaging in any ownership interest in any type of Auction Rate Security by Borrower or any of its Subsidiaries shall be conclusively
determined by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of
this Agreement governing Permitted Investments. Notwithstanding the foregoing, Cash Equivalents does not include and Borrower, and each
of its Subsidiaries, are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent
derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without
limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction
and more commonly referred to as an auction rate security (each, an &ldquo;<B>Auction Rate Security</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Claims</B>&rdquo;
are defined in Section&nbsp;12.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CME Term SOFR Administrator</B>&rdquo;
is CME Group Benchmark Administration Limited, as administrator of the forward-looking term SOFR, or any successor administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>CME
Term SOFR Administrator&rsquo;s Website</B>&rdquo;<B>&nbsp;</B>is the website of the CME Group Benchmark Administrator at&nbsp;<U>http://www.cmegroup.com</U></FONT>,
or any successor source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that,
to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different
Articles or Divisions of the Code, the definition of such term contained in Article&nbsp;or Division 9 shall govern; provided further,
that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies
with respect to, Collateral Agent&rsquo;s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction
other than the State of New York, the term &ldquo;Code&rdquo; shall mean the Uniform Commercial Code as enacted and in effect in such
other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for
purposes of definitions relating to such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral</B>&rdquo;
is any and all properties, rights and assets of Borrower described on <U>Exhibit&nbsp;A</U>, excluding all English Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Account</B>&rdquo;
is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary
which is a Borrower or Guarantor at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Agent</B>&rdquo;
is, Oxford, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commitment Percentage</B>&rdquo;
is set forth in <U>Schedule&nbsp;1.1</U>, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commodity Account</B>&rdquo;
is any &ldquo;commodity account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Communication</B>&rdquo;
is defined in Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compliance Certificate</B>&rdquo;
is that certain certificate in the form attached hereto as <U>Exhibit&nbsp;C</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Contingent Obligation</B>&rdquo;
is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a)&nbsp;any indebtedness, lease, dividend,
letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted
or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b)&nbsp;any obligations for undrawn
letters of credit for the account of that Person; and (c)&nbsp;all obligations from any interest rate, currency or commodity swap agreement,
interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest
rates, currency exchange rates or commodity prices; but &ldquo;Contingent Obligation&rdquo; does not include endorsements in the ordinary
course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the
Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in
good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Control Agreement</B>&rdquo;
is any control agreement entered into among the depository institution at which Borrower or any of its Subsidiaries maintains a Deposit
Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities
Account or a Commodity Account, Borrower or such Subsidiary, and Collateral Agent pursuant to which Collateral Agent obtains control
(within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Copyrights</B>&rdquo;
are any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and
derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Corporate Certificate</B>&rdquo;
is that certain certificate in the form attached hereto as <U>Exhibit&nbsp;E</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Credit Extension</B>&rdquo;
is any Term Loan or any other extension of credit by Lenders for Borrower&rsquo;s benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;CSSF&rdquo;
</B></FONT>is the Luxembourg Supervision Commission of the Financial Sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Default Rate</B>&rdquo;
is defined in Section&nbsp;2.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Deposit Account</B>&rdquo;
is any &ldquo;deposit account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Designated Deposit
Account</B>&rdquo; is Borrower&rsquo;s deposit account, account number ending (last 4 digits) 8631, maintained with Silicon Valley Bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disbursement Letter</B>&rdquo;
is that certain form attached hereto as <U>Exhibit&nbsp;B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Division</B>&rdquo;
means, in reference to any Person which is an entity, the division of such Person into two (2)&nbsp;or more separate Persons, with the
dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated
under Section&nbsp;18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, or
any analogous action taken pursuant to any other applicable law with respect to any corporation, limited liability company, partnership
or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Dollars</B><I>,</I>&rdquo;
 &ldquo;<B>dollars</B>&rdquo; and &ldquo;$&rdquo; each mean lawful money of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Domestic Subsidiary</B>&rdquo;
means a Subsidiary organized under the laws of the United States or any state or territory thereof or the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective Date</B>&rdquo;
is defined in the preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Eligible Assignee</B>&rdquo;
is (i)&nbsp;a Lender, (ii)&nbsp;an Affiliate of a Lender, (iii)&nbsp;an Approved Fund and (iv)&nbsp;any commercial bank, savings and
loan association or savings bank or any other entity which is an &ldquo;accredited investor&rdquo; (as defined in Regulation D under
the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies,
mutual funds, lease financing companies and commercial finance companies, in each case, which either (A)&nbsp;has a rating of BBB or
higher from Standard&nbsp;&amp; Poor&rsquo;s Rating Group and a rating of Baa2 or higher from Moody&rsquo;s Investors Service,&nbsp;Inc.
at the date that it becomes a Lender or (B)&nbsp;has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each
case of clauses (i)&nbsp;through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition
of any withholding or similar taxes; provided that notwithstanding the foregoing, &ldquo;Eligible Assignee&rdquo; shall not include,
unless an Event of Default has occurred and is continuing, (i)&nbsp;Borrower or any of Borrower&rsquo;s Affiliates or Subsidiaries or
(ii)&nbsp;a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent. Notwithstanding the foregoing,
(x)&nbsp;in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions
set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y)&nbsp;in connection with a Lender&rsquo;s
own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any
Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or
party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction;
provided that no such sale, transfer, pledge or assignment under this clause (y)&nbsp;shall release such Lender from any of its obligations
hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted
an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed, delivered and fully completed
by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent
reasonably shall require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>English Collateral</B>&rdquo;
is any and all properties, rights and assets of the Guarantors, the subject of the English Security Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>English
Security Document</B>&rdquo; means the all-asset debenture entered into by </FONT>Parent and the Collateral Agent incorporating first
ranking fixed and floating charges over all of the assets and undertaking of the Parent, as the same may from time to time be amended,
restated, modified or otherwise supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equipment</B>&rdquo;
is all &ldquo;equipment&rdquo; as defined in the Code with such additions to such term as may hereafter be made, and includes without
limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;</B></FONT><B>EU
Consolidated Financial Sanctions List&rdquo; </B>mean the consolidated lists of persons, groups and entities subject to EU financial
sanctions, maintained by the European Union&rsquo;s European External Action Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event of Default</B>&rdquo;
is defined in Section&nbsp;8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Existing Indebtedness</B>&rdquo;
is the indebtedness of Borrower to Silicon Valley Bank in the aggregate principal outstanding amount as of the Effective Date of approximately
Five Million Dollars ($5,000,000.00) pursuant to that certain Loan and Security Agreement, dated November&nbsp;19, 2020, entered into
by and between Silicon Valley Bank and Borrower, as amended, restated or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA&rdquo;</B>
means the United States Food and Drug Administration, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Final Payment</B>&rdquo;
is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest
to occur of (a)&nbsp;the Maturity Date, or (b)&nbsp;the acceleration of any funded Term Loan, or (c)&nbsp;the prepayment of a Term Loan
pursuant to Section&nbsp;2.2(c)&nbsp;or (d), equal to the original principal amount of such funded Term Loan multiplied by the Final
Payment Percentage, payable to Lenders in accordance with their respective Pro Rata Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Final Payment Percentage</B>&rdquo;
is (i)&nbsp;for Term A Loan (A)&nbsp;two and seventy-five hundredths percent (2.75%), if the Term D Loan is not made and (B)&nbsp;three
percent (3.00%), if the Term D Loan is made, (ii)&nbsp;for Term B Loan (A)&nbsp;two and fifty hundredths percent (2.50%), if the Term
D Loan is not made and (B)&nbsp;two and seventy-five hundredths percent (2.75%), if the Term D Loan is made, (iii)&nbsp;for Term C Loan,
(A)&nbsp;one and seventy-five hundredths percent (1.75%), if the Term D Loan is not made and (B)&nbsp;two percent (2.00%), if the Term
D Loan is made, (iv)&nbsp;for Term D Loan, one and fifty hundredths percent (1.50%) and (v)&nbsp;for Term E Loan, one and thirty hundredths
percent (1.30%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Foreign Subsidiary</B>&rdquo;
is a Subsidiary that is not a Domestic Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Fourth
Draw Period</B>&rdquo; is the period commencing on the later of (i)&nbsp;October&nbsp;1, 2024 and (ii)&nbsp;the date of occurrence of
the Fourth Draw Period Commencement Event and ending on the earlier of (i)&nbsp;December&nbsp;31, 2024 and (ii)&nbsp;the occurrence of
an Event of Default</FONT>; provided, however, the Fourth Draw Period shall not commence if on the date of occurrence of the Fourth Draw
Period Commencement Event, an Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fourth Draw Period
Commencement Event</B>&rdquo; is the receipt by Borrower of the final approval from the United States Food and Drug Administration for
Borrower&rsquo;s New Drug Application for Borrower&rsquo;s product candidate Ensifentrine, prior to December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Funding Date</B>&rdquo;
is any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American
Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other
statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which
are applicable to the circumstances as of the date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>General Intangibles</B>&rdquo;
are all &ldquo;general intangibles&rdquo; as defined in the Code in effect on the date hereof with such additions to such term as may
hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections
in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the
extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights
to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer
lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase
or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise),
insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance
and rights to payment of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Approval</B>&rdquo;
is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice,
of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authority</B>&rdquo;
is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body,
court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or
pertaining to government, any securities exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guarantor</B>&rdquo;
is any Person providing a Guaranty in favor of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guaranty</B>&rdquo;
is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise
supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo;
is (a)&nbsp;indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations
for surety bonds and letters of credit, (b)&nbsp;obligations evidenced by notes, bonds, debentures or similar instruments, (c)&nbsp;capital
lease obligations, and (d)&nbsp;Contingent Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Person</B>&rdquo;
is defined in Section&nbsp;12.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvency Act</B>&rdquo;
is the Insolvency Act of 1986, as amended, of the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvency Proceeding</B>&rdquo;
is any proceeding by or against any Person under the United States Bankruptcy Code, the Insolvency Act, or any other bankruptcy or insolvency
law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking
reorganization, arrangement, or other relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvent</B>&rdquo;
means not Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual Property</B>&rdquo;
means all of Borrower&rsquo;s or any Subsidiary&rsquo;s right, title and interest in and to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;its
Copyrights, Trademarks and Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating
manuals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all source code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all design rights which may be available to Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation,
to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Inventory</B>&rdquo;
is all &ldquo;inventory&rdquo; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter
be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process
and finished products, including without limitation such inventory as is temporarily out of any Person&rsquo;s custody or possession
or in transit and including any returned goods and any documents of title representing any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investment</B>&rdquo;
is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance
or capital contribution to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Key Person</B>&rdquo;
is each of Borrower&rsquo;s (i)&nbsp;Chief Executive Officer, who is David Zaccardelli as of the Effective Date, (ii)&nbsp;Chief Financial
Officer, who is Mark W. Hahn as of the Effective Date and (iii)&nbsp;Chief Medical Officer, who is Kathleen Rickard as of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Legal Reservations</B>&rdquo;
are: (a)&nbsp;the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement
by laws relating to insolvency, reorganisation and other laws generally affecting the rights of creditors; (b)&nbsp;the time barring
of claims under the Limitation Acts, the possibility that an undertaking to assume liability for or indemnify a person against non-payment
of UK stamp duty may be void and defences of set-off or counterclaim; and (c)&nbsp;similar principles, rights and defences under the
laws of the United States or the UK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lender</B>&rdquo;
is any one of the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lenders</B>&rdquo;
are the Persons identified on <U>Schedule&nbsp;1.1</U> hereto and each assignee that becomes a party to this Agreement pursuant to Section&nbsp;12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lenders&rsquo;
Expenses</B>&rdquo; are all audit fees and expenses, costs, and expenses (including reasonable and documented attorneys&rsquo; fees and
expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending,
negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with
appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Letter Agreement</B>&rdquo;
is that certain Prepayment Fee Letter dated as of the Effective Date by and between Collateral Agent and Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lien</B>&rdquo;
is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred
or arising by operation of law or otherwise against any property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><B>Limitation
Acts</B>&rdquo; are the Limitation Act 1980 and the Foreign Limitation Periods Act 1984.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Loan Documents</B>&rdquo;
are, collectively, this Agreement, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, the English Security
Document, the Letter Agreement, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person,
and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders
and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Loan Party</B>&rdquo;
is a co-Borrower or a Guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Lux SV</B>&rdquo; is defined in Section&nbsp;12.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Change</B>&rdquo; is (a)&nbsp;a material impairment in the perfection or priority of Collateral Agent&rsquo;s Lien in the Collateral
(or English Collateral) or in the value of such Collateral (or English Collateral); (b)&nbsp;a material adverse change in the business,
operations or condition (financial or otherwise) of Borrower, or of Borrower and its Subsidiaries taken as a whole; or (c)&nbsp;a material
impairment of the prospect of repayment of any portion of the Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Maturity Date</B>&rdquo;
is, for each Term Loan, October&nbsp;1, 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><B>New
Drug Application</B>&rdquo; means a new drug application, submitted to the FDA pursuant to 21 U.S.C. &sect; 355 seeking authorization
to market a drug in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Obligations</B>&rdquo;
are all of Borrower&rsquo;s obligations to pay when due any debts, principal, interest, Lenders&rsquo; Expenses, the Prepayment Fee,
the Final Payment, and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or arising from,
out of or under, this Agreement or, the other Loan Documents, or otherwise, and including interest accruing after Insolvency Proceedings
begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Collateral Agent, and
the performance of Borrower&rsquo;s duties under the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC</B>&rdquo;
is the U.S. Department of Treasury Office of Foreign Assets Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC Lists</B>&rdquo;
are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No.&nbsp;13224,
66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the
rules&nbsp;and regulations of OFAC or pursuant to any other applicable Executive Orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Operating Documents</B>&rdquo;
are, for any Person, such Person&rsquo;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&rsquo;s
jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a)&nbsp;if such Person
is a corporation, its bylaws in current form, (b)&nbsp;if such Person is a limited liability company, its limited liability company agreement
(or similar agreement), and (c)&nbsp;if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing
with all current amendments or modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Oxford</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Patents</B>&rdquo;
means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals,
reissues, extensions and continuations-in-part of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Payment Date</B>&rdquo;
is the first (1<SUP>st</SUP>) calendar day of each calendar month, commencing on November&nbsp;1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Perfection Certificate</B>&rdquo;
and &ldquo;<B>Perfection Certificates</B>&rdquo; is defined in Section&nbsp;5.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Acquisition</B>&rdquo;
means an acquisition pursuant to which Borrower acquires a Person or an ownership interest in a Person through the issuance of Borrower&rsquo;s
capital stock, so long as the number of shares or the voting power of Borrower&rsquo;s capital stock issued with respect to any one Peron
is less than twenty-five percent (25.00%) of the total shares or voting power of Borrower&rsquo;s capital stock outstanding before the
issuance, to the extent that each of the following conditions shall have been satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;immediately
prior to, and after giving effect thereto, no Event of Default shall have occurred and be continuing or would result therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
transactions in connection therewith shall be consummated, in all material respects, in accordance with applicable law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
acquired Person or assets shall be in the same line of business as is conducted by Borrower as of the Effective Date (or a line of business
reasonably related thereto);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
acquisition shall not cause the focus or locations of Borrower&rsquo;s and its Subsidiaries&rsquo; operations (when taken as a whole)
to be located outside of the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the case of the purchase or other acquisition of Shares, all of the Shares acquired or otherwise issued by such Person or any newly formed
Subsidiary in connection with such acquisition shall be wholly owned by Borrower or a Subsidiary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
connection with such acquisition, neither Borrower nor any of its Subsidiaries (including for this purpose, the target of the acquisition)
shall acquire or be subject to any Indebtedness or Liens that are not otherwise permitted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
cash consideration for the Permitted Acquisitions shall not exceed Seven Hundred Fifty Thousand Dollars ($750,000.00) in the aggregate
per fiscal year (subject to the limitation on changes of ownership of Borrower set forth in Section&nbsp;7.2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower
shall have delivered to the Collateral Agent and Lenders at least five (5)&nbsp;Business Days (or such shorter period as may be acceptable
to Collateral Agent and Lenders) prior to such proposed acquisition (i)&nbsp;a copy of the purchase agreement related to the proposed
acquisition (and any related documents reasonably requested by the Collateral Agent and Lenders), (ii)&nbsp;a general description of
the acquired assets or acquired business line or unit or division and the competitive position of such business line or unit or division
within the industry, (iii)&nbsp;the sources and uses of funds to finance the proposed acquisition, and (iv)&nbsp;to the extent available,
quarterly and annual audited financial statements of the Person whose Shares or assets are being acquired for the twelve (12) month period
immediately prior to such proposed acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
Permitted Acquisition shall only involve assets located in the United States or the United Kingdom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collateral
Agent and the Lenders have received a certificate from a Responsible Officer together with Board approved projections certifying and
setting forth in reasonable detail that Borrower has enough cash on hand to pay its projected expenses and all debt service when due
for a period of twelve (12) months after the consummation of such transaction (after giving effect to such transaction); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
Permitted Acquisition shall be consensual and shall have been approved by the target&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
to the contrary contained herein, in order for any acquisition of Shares or assets of another Person to constitute a Permitted Acquisition,
Borrower must comply with all of the following: (a)&nbsp;within thirty (30) Business Days of the closing of such Permitted Acquisition,
the applicable Borrower (or Subsidiary) making such Permitted Acquisition and the target shall have executed such documents and taken
such actions as may be required under Section&nbsp;6.12; (b)&nbsp;the applicable Borrower shall have delivered to Collateral Agent and
Lenders, in form and substance satisfactory to the Collateral Agent and Lenders and sufficiently in advance (and in any case no later
than five (5)&nbsp;Business Days prior to such Permitted Acquisition), such other financial information, financial analysis, documentation
or other information relating to such Permitted Acquisition and the pro forma certifications required by clause (c)&nbsp;below, in each
case, as Collateral Agent and Lenders shall reasonably request; (c)&nbsp;on or prior to the date of such Permitted Acquisition, the Collateral
Agent and Lenders shall have received, in form and substance reasonably satisfactory to the Collateral Agent and Lenders, a certificate
of the chief financial officer of Borrower certifying compliance with the requirements contained in this definition of &ldquo;Permitted
Acquisition&rdquo; and with the other terms of the Loan Documents (before and after giving effect to such Permitted Acquisition); and
(d)&nbsp;Borrower shall provide to the Collateral Agent and Lenders as soon as available but in any event not later than five (5)&nbsp;Business
Days after the execution thereof, a copy of the executed purchase agreement or similar agreement with respect to any such acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Indebtedness</B>&rdquo;
is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Borrower&rsquo;s
Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
existing on the Effective Date and disclosed on the Perfection Certificate(s);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subordinated
Debt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;unsecured
Indebtedness to trade creditors incurred in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries
to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i)&nbsp;the
aggregate outstanding principal amount of all such Indebtedness does not exceed Five Hundred Thousand Dollars ($500,000.00) at any time
and (ii)&nbsp;the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so
acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition,
repair, improvement or construction is made);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&rsquo;s business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unsecured
Indebtedness of Borrower with respect to corporate credit cards, not to exceed One Million Dollars ($1,000,000.00) in the aggregate outstanding
at any time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;letters
of credit in the ordinary course of business in an aggregate amount not to exceed Five Hundred Thousand Dollars ($500,000.00);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;intercompany
Indebtedness among Borrower and its Subsidiaries otherwise constituting (and without duplication with any clause of the definition of)
 &ldquo;Permitted Investments;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
consisting of the financing of insurance premiums in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indebtedness
incurred in the ordinary course of business in connection with workers&rsquo; compensation, unemployment insurance and other social security
legislation or in respect of surety and appeal bonds, performance bonds and other similar obligations (exclusive of obligations for the
payment of borrowed money); provided, however;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
unsecured Indebtedness not exceeding Five Hundred Thousand Dollars ($500,000.00) in the aggregate outstanding at any time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>extensions,
refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a)&nbsp;through (n)&nbsp;above, provided
that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon
Borrower, or its Subsidiary, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Investments</B>&rdquo;
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
disclosed on the Perfection Certificate(s)&nbsp;and existing on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;Investments
consisting of cash and Cash Equivalents held in Borrower&rsquo;s Collateral Accounts that are maintained in accordance with Section&nbsp;6.6
of this Agreement, and (ii)&nbsp;any other Investments permitted by Borrower&rsquo;s investment policy, as amended from time to time,
provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of Deposit Accounts in which Collateral Agent has a perfected security interest, except pursuant to the terms of Section&nbsp;6.6;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in connection with Transfers permitted by Section&nbsp;7.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(i)&nbsp;by Borrower in Subsidiaries which are Borrowers or Guarantors; (ii)&nbsp;by Borrower in Subsidiaries which are not Borrowers
or Guarantors, not to exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate per fiscal year; and (iii)&nbsp;of Subsidiaries
in or to Borrower or any Guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of (i)&nbsp;travel advances and employee relocation loans and other employee loans and advances in the ordinary course of
business, and (ii)&nbsp;loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries
pursuant to employee stock purchase plans or agreements approved by Borrower&rsquo;s Board of Directors, not to exceed Two Hundred Fifty
Thousand Dollars ($250,000.00) in the aggregate for (i)&nbsp;and (ii)&nbsp;in any fiscal year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates,
in the ordinary course of business; provided that this paragraph (h)&nbsp;shall not apply to Investments of Borrower in any Subsidiary;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to the extent constituting Investments, but without duplication with any
clause of the definition of, &ldquo;Permitted Indebtedness;&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
received as non-cash consideration with transactions otherwise permitted under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;non-cash
Investments in joint ventures or strategic alliances in the ordinary course of Borrower&rsquo;s business consisting of the licensing
of technology permitted under this Agreement, the development of technology or the providing of technical support;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in connection with joint ventures or strategic alliances or collaboration of Borrower or a Subsidiary; provided that any cash invested
in connection thereto shall not exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in connection with the entry into and performance of obligations under (including, for the avoidance of doubt, the payment of any premium
with respect to, and the settlement of) any Permitted Call Spread Transaction in accordance with its terms; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
Investments in an amount not to exceed Five Hundred Thousand Dollars ($500,000.00) in any fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Licenses</B>&rdquo;
are (A)&nbsp;licenses of over-the-counter software that is commercially available to the public, and (B)&nbsp;non-exclusive and exclusive
licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business
or approved by Borrower&rsquo;s Board of Directors, <U>provided</U>, that, with respect to each such license described in clause (B),
(i)&nbsp;no Event of Default has occurred or is continuing at the time of such license; (ii)&nbsp;the license constitutes an arms-length
transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict
the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise
Transfer any Intellectual Property; (iii)&nbsp;in the case of any exclusive license, (x)&nbsp;Borrower delivers ten (10)&nbsp;days&rsquo;
prior written notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders (provided, however,
Borrower&rsquo;s failure to deliver such prior notice and summary of terms despite its commercially reasonable efforts shall not constitute
an Event of Default if the applicable exclusive license otherwise complies with the terms hereof) and delivers to Collateral Agent and
the Lenders copies of the final executed licensing documents in connection with the exclusive license promptly upon consummation thereof,
and (y)&nbsp;any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects
other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United States; and (iv)&nbsp;all
upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or
any of its Subsidiaries are paid to a Deposit Account that is governed by a Control Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Liens</B>&rdquo;
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens existing on the Effective Date which are disclosed on the Perfection
Certificates or arising under this Agreement or the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
for taxes, fees, assessments or other government charges or levies, either (i)&nbsp;not due and payable or (ii)&nbsp;being contested
in good faith and for which Borrower maintains adequate reserves on Borrower&rsquo;s Books, provided that no notice of any such Lien
has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;liens
securing Indebtedness permitted under clause (e)&nbsp;of the definition of &ldquo;<B>Permitted Indebtedness</B>,&rdquo; provided that
(i)&nbsp;such liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20)&nbsp;days after
the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii)&nbsp;such
liens do not extend to any property of Borrower other than the property (and improvements and the proceeds thereof) acquired, leased
or built, or the improvements or repairs, financed by such Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long
as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed Five Hundred Thousand Dollars ($500,000.00),
and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings
which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
to secure payment of workers&rsquo; compensation, employment insurance, old-age pensions, social security and other like obligations
incurred in the ordinary course of business (other than Liens imposed by ERISA);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
incurred in the extension, renewal or refinancing of the Indebtedness secured by Liens described in (a)&nbsp;through (c), <U>but</U>
any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of
the indebtedness may not increase;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;leases
or subleases of real property granted in the ordinary course of Borrower&rsquo;s business (or, if referring to another Person, in the
ordinary course of such Person&rsquo;s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other
than Intellectual Property) granted in the ordinary course of Borrower&rsquo;s business (or, if referring to another Person, in the ordinary
course of such Person&rsquo;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent
a security interest therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;banker&rsquo;s
liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection
with Borrower&rsquo;s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar
costs and expenses and provided such accounts are maintained in compliance with Section&nbsp;6.6(b)&nbsp;hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
arising from judgments, orders, decrees or attachments in circumstances not constituting an Event of Default under Section&nbsp;8.4 or
8.7;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;deposits
to secure the performance of bids, trade contracts (other than for borrowed money), leases, statutory obligations, surety and appeal
bonds, performance bonds and other obligations of a like nature; in each case, incurred in the ordinary course of business and not representing
obligations for borrowed money, in an amount not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate outstanding
at any time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
on cash securing obligations permitted under clause (g)&nbsp;of Permitted Indebtedness; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
consisting of Permitted Licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment Fee</B>&rdquo;
is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration
or otherwise, an additional fee payable to the Lenders in amount equal to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such
Term Loan, two percent (2.00%) of the principal amount of such Term Loan prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the
second anniversary of the Funding Date of such Term Loan, one and fifty hundredths percent (1.50%) of the principal amount of the Term
Loans prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan through and including the
third anniversary of the Funding Date of such Term Loan, one percent (1.00%) of the principal amount of the Term Loans prepaid; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
a prepayment made after the third anniversary of the Funding Date of such Term Loan and prior to the Maturity Date, no Prepayment Fee
shall be applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pro Rata Share</B>&rdquo;
is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal
place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal
amount of all Term Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registered Organization</B>&rdquo;
is any &ldquo;registered organization&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Relevant Compartment</B>&rdquo; is defined
in Section&nbsp;12.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Required Lenders</B>&rdquo;
means (i)&nbsp;for so long as all of the Persons that are Lenders on the Effective Date (each an &ldquo;<B>Original Lender</B>&rdquo;)
have not assigned or transferred any of their interests in their Term Loan, Lenders holding one hundred percent (100%) of the aggregate
outstanding principal balance of the Term Loan, or (ii)&nbsp;at any time from and after any Original Lender has assigned or transferred
any interest in its Term Loan, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance of the
Term Loan and, in respect of this clause (ii), (A)&nbsp;each Original Lender that has not assigned or transferred any portion of its
Term Loan, (B)&nbsp;each assignee or transferee of an Original Lender&rsquo;s interest in the Term Loan, but only to the extent that
such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C)&nbsp;any Person providing financing to
any Person described in clauses (A)&nbsp;and (B)&nbsp;above; provided, however, that this clause (C)&nbsp;shall only apply upon the occurrence
of a default, event of default or similar occurrence with respect to such financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><B>Requirement
of Law</B>&rdquo; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty,
rule&nbsp;or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding
upon such Person or any of its property or to which such Person or any of its property is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Responsible Officer</B>&rdquo;
is any of the President, Chief Executive Officer, or Chief Financial Officer of Borrower acting alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Sanctioned
Country&rdquo;</B></FONT> is a&nbsp;country subject or target to a sanctions program identified&nbsp;on the&nbsp;list&nbsp;maintained
by&nbsp;OFAC, adopted by the EU, the UN, the CSSF or any other authority, or identified under any Anti-Terrorism Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Second Draw Period</B>&rdquo;
is the period commencing on the Effective Date and ending on the earlier of (i)&nbsp;March&nbsp;31, 2023 and (ii)&nbsp;the occurrence
of an Event of Default that continues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secured Promissory
Note</B>&rdquo; is defined in Section&nbsp;2.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secured Promissory
Note Record</B>&rdquo; is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender and
credits made thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Account</B>&rdquo;
is any &ldquo;securities account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Shares</B>&rdquo;
is one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record
by Borrower or Borrower&rsquo;s Subsidiary, in any Subsidiary; provided that, in the event Borrower, demonstrates to Collateral Agent&rsquo;s
reasonable satisfaction, that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary which is a Foreign Subsidiary,
creates a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code, &ldquo;Shares&rdquo; shall mean
sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by
Borrower or its Subsidiary in such Foreign Subsidiary</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Solvent</B>&rdquo;
is, with respect to any Person: the fair salable value of such Person&rsquo;s consolidated assets (including goodwill minus disposition
costs) exceeds the fair value of such Person&rsquo;s liabilities; such Person is not left with unreasonably small capital after the transactions
in this Agreement; and such Person is able to pay its debts (including trade debts) as they mature in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subordinated Debt</B>&rdquo;
is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and/or its Subsidiaries
to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral
Agent and the Lenders entered into between Collateral Agent, Borrower, and/or any of its Subsidiaries, and the other creditor), on terms
acceptable to Collateral Agent and the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo;
is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the
case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(v)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term&nbsp;A Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(i)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term&nbsp;B Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(ii)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term&nbsp;C Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(iii)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term&nbsp;D Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(iv)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term&nbsp;E Loan</B>&rdquo;
is defined in Section&nbsp;2.2(a)(v)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan Commitment</B>&rdquo;
is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on <U>Schedule&nbsp;1.1</U>.
 &ldquo;<B>Term Loan Commitments</B>&rdquo; means the aggregate amount of such commitments of all Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third Draw Period</B>&rdquo;
is the period commencing on the later of (i)&nbsp;January&nbsp;1, 2024 and (ii)&nbsp;the date of occurrence of the Third Draw Period
Commencement Event and ending on the earlier of (i)&nbsp;March&nbsp;29, 2024 and (ii)&nbsp;the occurrence of an Event of Default; provided,
however, the Third Draw Period shall not commence if on the date of occurrence of the Third Draw Period Commencement Event, an Event
of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third Draw Period
Commencement Event</B>&rdquo; is the receipt by Borrower of positive ENHANCE-1 data in the Phase 3 clinical trial for Borrower&rsquo;s
product candidate Ensifentrine sufficient to support the submission for a New Drug Application with the United States Food and Drug Administration
for Ensifentrine, which must be confirmed in writing in the minutes of the Board of Directors of Borrower (certified to Collateral Agent
by Borrower&rsquo;s Responsible Officer) on or prior to March&nbsp;29, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trademarks</B>&rdquo;
means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like
protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer</B>&rdquo;
is defined in Section&nbsp;7.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><B>U.S.
Person</B>&rdquo; means any Person that is a &ldquo;United States person&rdquo; as defined in Section&nbsp;7701(a)(30) of the Tax Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>US Sub</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page&nbsp;Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have caused this Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER:</B>&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VERONA PHARMA PLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%"></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Zaccardelli</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Zaccardelli</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VERONA PHARMA,&nbsp;INC.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Zaccardelli</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Zaccardelli</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER AND COLLATERAL AGENT:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OXFORD FINANCE LUXEMBOURG S.&Agrave; R.L.,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting in respect of its Compartment 7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Laurent
    Belik</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laurent Belik</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Melanie
    Florsch </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melanie Florsch</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[<I>Signature Page&nbsp;to
Loan and Security Agreement</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE&nbsp;1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Lenders and Commitments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of Collateral</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form&nbsp;of Disbursement Letter</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Compliance Certificate</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form&nbsp;of Secured Promissory Note</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form&nbsp;of Corporate Certificate</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vrna-20221014.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOOmbOdzZR+qYkxtmB2bRmKDywgihYEXiT+hYZmIXUA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:vrna="http://veronapharma.com/20221014" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20221014">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://veronapharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="vrna-20221014_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="vrna-20221014_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vrna-20221014_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vrna-20221014_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:href="vrna-20221014.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://veronapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140141362115184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 14,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona
Pharma plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3
More London Riverside<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283
4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
    shares, nominal value &#163;0.05 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm2227932d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vrna-20221014.xsd" xlink:type="simple"/>
    <context id="From2022-10-14to2022-10-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-14to2022-10-14">0001657312</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-14to2022-10-14">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-14to2022-10-14" id="xdx2ixbrl0012">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry contextRef="From2022-10-14to2022-10-14" id="xdx2ixbrl0018">GB</dei:EntityAddressCountry>
    <dei:DocumentType contextRef="From2022-10-14to2022-10-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-14to2022-10-14">2022-10-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-10-14to2022-10-14">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="From2022-10-14to2022-10-14">001-38067</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-14to2022-10-14">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-14to2022-10-14">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-14to2022-10-14">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-14to2022-10-14">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion contextRef="From2022-10-14to2022-10-14">44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="From2022-10-14to2022-10-14">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-14to2022-10-14">283 4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-10-14to2022-10-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-10-14to2022-10-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-10-14to2022-10-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-10-14to2022-10-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-10-14to2022-10-14">Ordinary     shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-14to2022-10-14">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-14to2022-10-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-14to2022-10-14">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-10-14to2022-10-14">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;QWO?06V,+A NXUQ5/. CYMXWD C6*?N3PHN$'@M#*2: 'S<N6]E"-69KJ7
M9J0&D:#7.FK#0ALCJFS?Q]WZF^+&, &)29),;,U5UU+A0DWK";^R?!]WZ+F,
M><@-%RMR!S:J.(UK>7"5)IZ@LO@ -^&I8B<AI(>)D!7+/EAYP0+U8;FLKU^#
M7B-9Y>L!;L(?R&ZTSH"L$1"7;03<6<CCUOO(#:R]Y)+XP6^+W\F<A1GT6ZU?
M-B@]J(@+V"D>$?C3L/)AX'9"PB8('JAG&F>,V/5]ZY-WZG5("J//;_H#&T9E
M^P%NUH^*1K8=YZ_)0M8V8X/ T^Q^A)%4?A\TN/,V@V3R$JZI6+&]2\@&H?O1
M_&KT%\94N7R F_1V#IHD3*ULECZ#@EE;1TFIJ*\U+FA4AK9?Y?M!PP; ;O=9
M1.XE/+22?-6,F#6#W!G[@$0$ZBHTSY>3Q>ZE%A;_C7VP[LXVW+[2N*,V.YK$
M; DZWND9Y$ 5;PF*$R/3?&>^D ;V^?GAFE%XCNT-\/U22O-V8C?[Y;N:X?]0
M2P,$%     @ $S!159^@&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M
M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>Q
MS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G
M55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4
M)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(R
MA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[
M##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R
M 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[T
MH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<
MO(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q
M]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**
M==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9
MQP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR
M'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<
M8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)
MQI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY[
M'R73>RHY_U=3_ 102P,$%     @ $S!159>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  3,%%5JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( !,P455ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  3,%%5)!Z;HJT   #X 0
M&@              @ 'Y$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  3,%%599!YDAD!  #/ P  $P              @ '>$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   H%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2227932d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode -  tm2227932d1_8k.htm 21</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="tm2227932d1_8k.htm">tm2227932d1_8k.htm</File>
    <File>tm2227932d1_ex10-1.htm</File>
    <File>vrna-20221014.xsd</File>
    <File>vrna-20221014_lab.xml</File>
    <File>vrna-20221014_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2227932d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2227932d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20221014_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20221014_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20221014.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20221014",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2227932d1_8k.htm",
      "contextRef": "From2022-10-14to2022-10-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2227932d1_8k.htm",
      "contextRef": "From2022-10-14to2022-10-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-22-108980-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-108980-xbrl.zip
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M5R[0]Q&W+/W]T9,FR!.EF*;G.'P4 .[ZDZQ3O EUJOXFM/14-\(/;9,[6K"
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MX-\98ZTIG^/  ,#_YU7$H]7F"Y%VU_.!HZJ^ZM.:!GSETN0!47M,+C19^5P
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MHTQ1-9!%/NA#P_%Q./!\D%JK],IB_86WZ];+]X2V^OK%AS6KK:?;97O7[)$
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MB1'DUI0!;L-7U4/=>R=69+[+%1FLP7%U6B)N:]/L*SKK+S#YU3<X#CT'0U>
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MMMB;:=VVBIG13713!89 @#KO;9%3D2^T%6AR=KH78%V_.'0VT][C(RRO  R
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MH[NY8N?/VQG?[W!GG&1?QJ,/IELVPG;]7LCV7H UQ-TPCSP;JT\&?ZD?BS!
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MI*)E*N]G']X6@06(F]C+P3L\5"F]93/)#&26)*I7'U TVY /.4% @^SG_BF
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MF9QJ5'?2L 'K,D$GQZ[S$TLIYJ\7>"=2E#,42>^.0378@CG(N1![>?![+^8
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MPX1R':91GIYG5<[0CLRA)-!S/T$0A;#\]6=8 @QS'[XS<%;>,-A=9]!%%6"
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M2LMA"AD#AMB) AL2Y_4->.?MI>N"^;0,3=L:+V5#PD=)>P'!3R1,95P3&K)
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M6;1@'K$?/@Z$!_H-[A$[69[3Z/,I%JW]KY?QYN:F_F]C<W-=E4"EM@_[D**
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ME&67UQ6*P3.)@@B?R,YZ; +:77H)F#YT0@D8D*NL3D)7O9$\\%6CYDK;X3F
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M*N YEE1(B#-P2[%D'K1((5PYF+.D\FV;M;J1!Z"+!0#65CY\AA[:U"&B&G0
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MQ3V:3>7SK?#O=X[V_OD:_^/WT[<'K_\?4$L#!!0    ( !,P457QJ6T=/0,
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M66%@T<1.M6LP.BSKC%BD0>$"^P/;CCH$[6-\K+99++LF7R7 UX6'"_'!4E)
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2      4 !0!) 0  YR,!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
